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InTRoducTIon In TReaTmenT of HIV-1
The rationale for immediate treatment initiation in HIV-1 infection
By initiating combination antiretroviral therapy (cART) early after the HIV diagnosis, almost 
all individuals achieve a suppressed plasma HIV viral load. This prevents the progression to an 
immunodeficient state due to loss and dysfunction of CD4 T-lymphocytes and, eventually, the 
Acquired Immune Deficiency Syndrome (AIDS).1–5 The START and the TEMPRANO stud-
ies provided the important insight that immediate initiation of cART after the HIV diagnosis, 
irrespective of CD4 T-lymphocyte counts, results in a better outcome than deferring cART 
initiation until CD4 T-lymphocytes drop below 350 cells/mm3. This benefit is not only the 
consequence of a reduction in AIDS-related morbidity and mortality, but also of a reduction 
in non-AIDS-related morbidity and mortality.6–8 These landmark studies led to the universal 
recommendations to initiate cART immediately after an HIV-diagnosis, regardless of CD4 
T-lymphocytes count, which is in contrast with the previous recommendation to start cART 
below certain thresholds of CD4 T-lymphocytes.9 Apart from the health benefit for the HIV 
infected patient, uninfected individuals benefit from treatment of HIV as well. People with a 
suppressed plasma HIV viral load as the consequence of cART have a negligible chance of 
transmitting HIV by sexual or vertical (mother to child, in utero, or peripartum or postpartum) 
transmission.10–12 Thus, cART prevents development of AIDS and death, diminishes loss of 
immunity, and protects HIV uninfected individuals. The earlier cART is initiated during the 
course of an HIV-infection, the more advantageous it is expected to be.
The HIV replication cycle and antiretroviral resistance
HIV is an RNA lentivirus, belonging to the retrovirus subfamily. These viruses are charac-
terized by the need of reverse transcription of viral RNA to synthesize viral DNA, which 
is part of their replication cycle. The replication cycle of HIV starts with binding of viral 
glycoprotein 120 (Gp120) to the surface of the CD4 T-lymphocyte. Thereafter, transforma-
tion of Gp120 enables binding of the virus to a co-receptor on the CD4 T-lymphocyte: the 
CCR5-receptor or the CXCR4-receptor. This enables viral Gp41 to fuse with the cell mem-
brane, which is followed by the release of viral RNA and viral enzymes into the cytoplasm. 
After the formation of double-stranded HIV-DNA catalyzed by reverse transcriptase (RT), 
viral DNA, viral proteins, and host factors enter the nucleus. This so-called pre-integration 
complex (PIC) is integrated into the host DNA by the viral enzyme integrase. Transcription 
of this integrated HIV-DNA results in the formation of unspliced RNA or messenger RNA 
(mRNA), which then enters the cellular cytoplasm. The mRNA encodes for viral structural 
proteins and enzymes. Together with unspliced viral RNA, these proteins form a new free 
viral particle after successful assembly and detachment from the cell surface. Viral protease 
helps maturing the viral particle in order to be able to infect another cell.13 Non-mutated viral 
strains, which are called wildtype viral strains, are considered to have the highest competence 
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to complete their replication cycle. The competence to complete the replication cycle is also 
called viral fitness. Viral fitness often becomes reduced when the virus mutates, compared 
to wildtype viral strains (‘wildtype’).14 Development of mutations in the genome, causing 
resistance, is an important survival-mechanism of HIV to evade antiretroviral drugs. When a 
viral strain is susceptible to a specific antiretroviral agent, suppression of plasma HIV-RNA 
is the result from interruption of the HIV replication cycle by that antiviral agent. Resistance 
means that mutations lead to suboptimal interruption of the HIV replication cycle by an anti-
retroviral drug, compared to wildtype virus at similar concentrations of cART. A distinction 
can be made between phenotypic and genotypic resistance. Genotypic resistance refers to the 
presence of resistance associated mutations (RAMs), whereas phenotypic resistance refers 
to the drug susceptibility of the virus by determining the concentration of an antiretroviral 
agent that inhibits viral replication. There are two mechanisms responsible for development 
of RAMs causing treatment failure: i) the rapid viral replication with the error prone reverse 
transcriptase-step causes random mutations which can be RAMs resulting in clinical sig-
nificant resistance against cART even before treatment initiation and ii) RAMs that develop 
during cART, especially in settings with inadequate drug levels. The underlying mechanism 
of treatment failure is of importance for the selection of an adequate antiretroviral regimen. 
If the resistance to antiretroviral drugs is transmitted, the only possibility to achieve viral 
suppression is to initiate a cART-regimen consisting of antiretroviral agents with full antiviral 
activity. If the virus obtained mutations leading to antiretroviral resistance, the combination 
of an increased dose of the antiretroviral drug and the other antiretroviral drugs may result in 
viral resuppression.15
antiretroviral drugs and treatment targets
Worldwide, five HIV treatment guidelines are commonly used.16–20 In general, six classes 
of antiretroviral drugs are available: CCR5 antagonists, fusion inhibitors (FI), nucleoside 
reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), integrase strand transfer inhibitors (INSTI), and protease inhibitors (PI). Figure 
1 shows the HIV-1 replication cycle, including the different drug targets and antiretroviral 
drug classes. The different classes of antiretroviral drugs, including the individual drugs, are 
listed in Table 1. Only those that are in use in the Netherlands are provided. Table 2 provides 
an overview of the different recommended first-line antiretroviral treatment-regimens in five 
commonly used HIV treatment guidelines.
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Figure 1. HIV-1 replication cycle. The white boxes indicate antiretroviral drug targets and accessory antiretro-
viral drug classes. Reproduced with permission from Walker et al.21
14 Chapter 1
Drug class (abbreviation) Name Abbreviation
CCR5 antagonist Maraviroc MVC
Fusion inhibitor (FI) Enfuvirtide T20




Tenofovir disoproxil fumarate TDF
Tenofovir alafenamide fumarate TAF
Zidovudine ZDV



















Pharmacoenhancer Cobicistat /c or COBI
Ritonavir$ /r or RTV
Table 1. Available antiretroviral drugs for treatment of HIV. $ Ritonavir is a protease inihibitor, which was 
initially used as antiretroviral drug, but currently only is used as pharmacoenhancer.
In general, all guidelines recommend to initiate cART consisting of two NRTIs combined 
with a third agent, either an NNRTI, a PI boosted with a pharmacoenhancer, or an INSTI. 
Boosters inhibit the activity of cytochrome P450 (CYP450) enzymes which metabolize PI 
and EVG. This increases the plasma levels of PIs and EVG and reduces the necessary doses 
needed to achieve adequate plasma levels for virological suppression. The PI RTV differs 
from COBI because, unlike COBI, it is a booster with antiretroviral activity, especially when 
given in a therapeutic dosage. RTV also has an increased risk for gastro-intestinal side effects, 
dyslipidemia, and it inhibits multiple CYP450 coenzymes, whereas COBI is a more spe-
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cific CYP450 inhibitor.22 In contrast to RTV, COBI is an inhibitor of renal tubular creatinine 
excretion, by inhibition of tubular creatinine-transporter MATE-1, causing increased serum 
creatinine without truly affecting renal or glomerular function.23
Differences exist between HIV treatment guidelines. Whereas the American guideline DHHS 
recommends to initiate INSTI-containing cART-regimens as first line, the European guideline 
EACS recommends other non-INSTI regimens as well. Both the American and European 
guidelines make no distinction between ABC/3TC, TAF/FTC, or TDF/FTC as NRTI-back-
bone. However, when peak HIV-RNA is above 100.000 copies/mL (c/mL) and ATV/r or c, 
EFV, and RPV is considered as third agent, an ABC-containing backbone is not the preferred 
option in both guidelines. In resource-poor countries, the WHO-guideline is mostly used, 
which recommends an NNRTI-containing regimen, or DTG combined with NRTI backbones 
as alternative regimens. The limited availability of TAF and INSTI in resource-limited coun-
tries explains the differences between the WHO-guideline and the American and European 
Guidelines16–20
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Guideline Drug classes Drugs
Department of Health and Human 
Services (DHHS)16




World Health Organisation 
(WHO)17
2 NRTIs + NNRTI (preferred)
2 NRTIs + NNRTI (alternative)





European AIDS Clinical Society 
(EACS)18
2 NRTIs + INSTI
2 NRTIs + NNRTI







TAF/FTC/DRV/c or /r or TDF/FTC/
DRV/c or /r
British HIV Association19 2 NRTIs + INSTI
2 NRTIs + NNRTI







International Antiviral Society-USA 
(IAS-USA)20
2 NRTIs + INSTI ABC/3TC/DTG
TAF/FTC/BIC
TAF/FTC/DTG
Table 2. Overview of recommended first-line antiretroviral treatment-regimens in different HIV treatment 
guidelines. For the abbreviations, see Table 1.
Of course, the choice of which cART-regimen is initiated is a multifactorial decision of an 
HIV-treating physician with an individual patient, in which co-infections, comorbidity, sex 
(in relation to potential future pregnancies), use of concomitant medication, costs, and behav-
ioral aspects should be taken into account. However, INSTI have become preferential agents 
for cART in resource-rich countries. An important advantage of initiating INSTI-containing 
cART is the very low risk of transmitted INSTI resistance mutations in the integrase gene, 
affecting INSTI efficacy, both on the viral population level and in viral subpopulations.24 
This contrasts with the prevalence of transmitted NRTI and NNRTI resistance.25,26 Therefore, 
INSTI-containing cART could be initiated soon after HIV-diagnosis, unless there are risk 
factors for transmitted INSTI-resistance.16,18,20 Additionally, the low risk of drug-drug-
interactions and adverse events (AE), and the high genetic barrier against the development 
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of resistance of the second generation INSTIs (all discussed in detail later) further favor 
the recommendation to initiate INSTI-containing cART.27–29 Since 2016, the consensus of 
HIV-treatment guidelines for resource-rich countries is to initiate INSTI-based regimens in 
cART-naive HIV-infected individuals, and this was followed by a worldwide uptake of INSTI 
based first-line treatments, in resource-rich countries.16–20
HIV treatment strategies and treatment simplification – a historical perspective
From the mid-80s until the early 2000s, studies investigating the virological efficacy of a 
new single NRTI or NNRTI therapy were conducted in cART naive patients, to evaluate the 
potency of these drugs.30–32 Unfortunately, within a period of weeks, resistance associated 
mutations emerged with NRTI and NNRTI monotherapies.30,32,33 Subsequent studies on dual 
and triple cART showed more durable virological responses without RAMs in most patients, 
although VF still occurred.34–39 Preservation of virological suppression with cART improved 
when cART consisted of two NRTIs combined with an NNRTI, PI, or more recently IN-
STI.40–42
definitions
The main rationale behind the treatment of HIV infected individuals with cART consisting 
of three antiretroviral drugs targeting at least two targets in the HIV replication cycle (triple 
cART) is to suppress viral replication as efficacious as possible, to induce a sustained plasma 
viral suppression, and to minimize the risk of virological failure (VF) by the development of 
resistance. Different definitions of VF have been used. In phase 3 studies, virological suppres-
sion has often been defined as a plasma HIV-RNA below c/mL, although guidelines consider 
virological suppression as an undetectable plasma HIV-RNA, which means that the HIV-RNA 
has to be below the limit of detection of the local laboratory thresholds. These thresholds vary 
between 20 and 50 c/mL. Detectable plasma HIV-RNA may lead to development of RAMs, 
leading to a reduced susceptibility of the virus to that agent, which is permanent, even after 
resuppression of the virus with other agents. The consequence of RAMs is, that also in the 
future, treatment with the particular agent is not possible. Sometimes, a temporary increase of 
plasma HIV-RNA during use of antiretroviral therapy occurs, a blip or viral rebound. A blip 
is usually defined as a temporary increase of the plasma viral load from undetectable to 50 to 
200 c/mL. A viral rebound means a substantial amount of detectable plasma HIV-RNA, and 
the virus might spontaneously get resuppressed again. Although the effects of viral rebounds 
below 20.000 c/mL on the risk of development of an AIDS-defining illness are shown to be 
small, low-level viremia is a risk factor for future VF and viremia is associated with elevated 
pro-inflammatory markers.43–45
Simplification of HIV treatment has always been an important subject of research. Simplifica-
tion can consist of the reduction in the number of pills and/or the number of antiretroviral 
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agents. However, reasons to simplify therapy to reduce AE, pill burden, or costs, should not 
or only minimally increase the risk of VF. A decade after the introduction of triple cART in 
1996, the concept of simplification of cART was investigated with PI monotherapy, because 
PIs have a higher genetic barrier against resistance than NRTIs and NNRTIs.46–48 The results 
of the first of these PI-monotherapy studies were promising, but larger studies eventually 
showed that PI monotherapy was not the golden bullet. A landmark-study on PI monotherapy 
is the PIVOT-study.49 In this open-label non-inferiority study, 587 patients were randomized 
to continuation of cART or to a switch to PI monotherapy, either DRV/r or LPV/r. The patients 
were suppressed (plasma HIV-RNA below 50 c/mL) on triple cART with NNRTI or PI plus 
2 NRTI, and they had a CD4 T-lymphocyte count higher than 100 cells/mm3. Furthermore, 
they had no PI RAMs or previous VF, which means that their virus should have had optimal 
susceptibility to PIs, and that patients were likely to be adherent. These characteristics are 
considered essential for simplified antiretroviral regimens to work. VF during the study was 
defined as three consecutive HIV-RNA measurements higher than 50 c/mL, of which the 
second one was one week after the first measurement, and the third measurement was four 
weeks after the first one. The primary endpoint of the study was loss of future cART treatment 
options after three years of follow-up. This was defined as acquired resistance to the PI. After 
a median follow-up of 44 months, 2/291 patients in the cART-group and 6/296 patients in 
the PI monotherapy group lost future treatment options, which proved non-inferiority of the 
PI-monotherapy strategy. In 8/291 patients in the cART-group, but in 95/296 patients in the 
PI monotherapy group, plasma HIV-RNA became detectable again at least once. This viral 
rebound in the PI-group often occurred in the first year, and in all patients with available 
follow-up, spontaneous resuppression on monotherapy or resuppression after the addition of 
two NRTIs (which means re-initiation of cART) occurred. In conclusion, this study showed 
that in the setting of a clinical trial, PI monotherapy as a simplification strategy in patients 
who are suppressed on cART rarely leads to the loss of future treatment options, because 
even if a viral rebound occurs, viral resuppression occurs in almost all patients. However, the 
effect of viral rebounds on the inflammation markers and the risk on future VF were not dis-
cussed. Furthermore, the very frequent VL monitoring, which was part of the study protocol, 
makes it difficult to extrapolate the study results to real-life, as patients typically have their 
VL monitored twice a year when they are stable on cART. A number of other randomized 
clinical trials was performed to compare the virological efficacy of boosted PI maintenance 
monotherapy with PI-containing triple cART, and in 2015 a meta-analysis was published. 
This study analyzed 13 randomized clinical trials, investigating PI maintenance monotherapy 
versus triple cART in patients with suppressed HIV-RNA prior to PI monotherapy initiation 
and included a total of 2303 patients. Patients switched to monotherapy with DRV/r (4 stud-
ies, N=784), LPV/r (7 studies, N=829), ATV/r (1 study, N=103), or were allowed to switch to 
one of the three mentioned PIs (PIVOT study, N=587). The authors considered a switch from 
monotherapy to triple therapy as treatment failure, and the absolute difference in percentages 
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of treatment failure between PI monotherapy and cART was -8.3% (73.9 versus 82.0%, 95% 
confidence interval (CI) -4.8% to -11.9%), and was statistically significant (p<0.0001). In a 
switch-included-analysis, in which a confirmed elevation of HIV-RNA higher than 50 c/mL 
was defined as treatment failure, but intensification of PI monotherapy to cART was not, 
no significant difference in virological suppression was observed. Furthermore, the risk of 
development of any NRTI or PI RAMs was low (1.3% in PI monotherapy and 0.6% in cART) 
and comparable between groups. However, the results of the PIVOT trial were not included in 
this resistance analysis, as they were not yet available.50 The results of this meta-analysis were 
therefore not convincingly in favor of PI monotherapy nor against the use of PI monotherapy. 
Disadvantages which hampered the global introduction of PI monotherapy were concerns re-
garding insufficient virological suppression, the fact that boosted PIs monotherapy still meant 
two or more large pills, the occurrence of AEs, and the potential for drug-drug-interactions. 
However, the concept of monotherapy remained appealing, and with the introduction of 
INSTIs this strategy was reconsidered. INSTIs have better tolerability and less drug-drug-
interactions than PIs. In 2013, the second-generation INSTI DTG became available. With 
the availability of DTG with its high genetic barrier to resistance, new possibilities regarding 
treatment-simplification maintenance therapy became available. To provide insights in the 
favorable properties of INSTIs, and differences between drugs within this antiretroviral class, 
the INSTIs are described in more detail in the next chapter.
VIRal InTegRase and InTegRase sTRand TRansfeR InHIbIToRs
Viral integrase
A pivotal step in the replication cycle of the retrovirus HIV is the integration of HIV-DNA 
in the host DNA of infected cells. After integration, transcription initiation of viral genes 
results in mRNA and production of viral proteins and eventually new viral particles that can 
infect other cells. The viral enzyme integrase enables integration of the proviral DNA into 
the host DNA. Integrase is a 32kDa amino-acid, encoded by the viral pol gene. It is produced 
as part of the gag-pol polypeptide precursor by viral protease.51 Integrase acts as multimer, 
usually as dimer, which consists of two integrase-proteins, or as tetramer, which consists 
of four integrase-proteins. It has three functional domains:52–58 i) the N-terminal domain, 
which consists of amino acids 1-46. The exact function of the N-terminal domain in the 
integration-process has currently not been fully elucidated. However, the domain carries a 
HHCC motif (because of the His and Cys residues it contains), and the HHCC motif is neces-
sary for binding of the N-terminal domain to zinc, which is subsequently needed for optimal 
3’-processing and the strand transfer step. The N-terminal domain is also involved in forma-
tion of integrase-multimers (multimerization). ii) The central core domain, which consists of 
amino acids 56-212. The central core domain of integrase is considered the most important 
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part of the enzyme. The central core domain encompasses a D,D-35-E motif (responsible 
for the arrangement of the D64, D116, and E152 acidic amino acid residues)59, which is 
pivotal for the binding of integrase to the host DNA and the catalytic activity of the integrase 
process. The central core domain contains two divalent cations (often magnesium (Mg2+) or 
manganese (Mn2+)), which are needed as cofactor for 3’-processing and to destabilize target 
DNA for integration.60 Furthermore, the core domain is also involved in multimerization, 
and it promotes the disintegration process (see below). iii) The C-terminal domain, which 
consists of amino acids 195-288. The C-terminal domain also is involved in multimerization, 
it binds to random localizations in the DNA, and is mainly responsible for the stability of 
the viral-host-DNA-complex.61 Figure 2 shows a schematic overview of the structure of the 
HIV-1 integrase.62
Figure 2. Schematic presentation of the structure of HIV-1 integrase. NTD=N-terminal domain; CCD=catalytic 
core domain; CTD=C-terminal domain. Reproduced with permission from Kessl et al.62
Integration of viral dna into host dna
Integration of viral DNA into host DNA is a two-step mechanism. First, integrase binds to 
both ends of the viral DNA, the long terminal repeats (LTR), forming the PIC. After binding 
to the LTR, integrase catalyzes a process of cleavage of two nucleotides from each 3’-end 
of the viral DNA. This is known as 3’-processing. After this step, the DNA is integrated 
into the DNA of the host cell by a strand transfer step, which is characterized by ‘cuts’ in 
the host DNA, creating 5’-protrusions, followed by binding of the viral 3’-ends and the host 
5’-ends. It is likely that the position at which the viral DNA integrates into the host DNA 
is not random, but that it preferentially integrates into active transcription sites, in order to 
promote viral gene expression after integration.63 The integration is completed by removal of 
the unpaired nucleotides at the 5’-ends of the viral DNA and repair of single gaps between 
viral and host DNA. The whole process of integration-strand-transfer is accompanied in vitro 
with the step of disintegration, which seems not to occur in vivo. This step is characterized by 
a reversed strand transfer step, resulting in the release of viral DNA from the host DNA and 
repair of the host DNA strand.51, 57, 64 The exact role of the disintegration-step has to be further 
elucidated in vivo. The whole process of integration of HIV DNA into host DNA is presented 
schematically in Figure 3.65
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Integrase strand transfer inhibitors
The antiretroviral effect of INSTIs is the result of inhibition of the strand-transfer step. 
INSTIs do not influence the binding between integrase and viral DNA and 3’-processing, 
but they bind to the PIC and subsequently inhibit the strand transfer reaction. The unique 
property of INSTIs compared to other antiretroviral agents is that both viral integrase and 
viral pre-integrated DNA are needed as a complex for the INSTIs to bind to, as INSTIs cannot 
bind to one of those factors individually.66 The binding of INSTIs results both in cleavage of 
Mg2+, which inactivates integrase’s catalytic function, and to displacement of the 3’-hydroxyl 
end of the viral DNA-strands.60,67 In conclusion, the inhibition of the strand transfer step by 
INSTIs is the result of i) their binding to the viral integrase, with ii) concomitant binding 
to the 3’LTR region of viral DNA, resulting in iii) inhibition of PIC-host DNA complex 
formation. All INSTIs have two components of major importance: a metal-binding part which 
cleaves the Mg2+-ions of integrase, and a hydrophobic part which interacts with the viral DNA 
and the integrase. Especially the hydrophobic components are important for the affinity and 
specificity of the INSTI-viral DNA-integrase-complex.60
Figure 3. Schematic overview of integration of viral DNA into the host DNA. Reproduced with permission 
from Métifiot et al.65
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Integrase strand transfer inhibitor resistance
Although increasing, the prevalence of transmitted INSTI-resistance mutations is low.25,26,68–71 
With a few exceptions, INSTI-resistance is typically caused by RAMs occurring during 
viremia in the setting of inadequate plasma INSTI-concentrations, caused by suboptimal 
adherence to antiretroviral drugs, or insufficient drug penetration. An overview of INSTI-
RAMs, including their effect on INSTI-susceptibility according to the Stanford University 
Drug Resistance Database is shown in Table 3.72
mutation associated with INSTI-resistance reduction of INSTI-susceptibility
major primary mutations
T66A/I/K RAL: 10-20 fold by T66K
EVG: 10-40 fold
DTG: 2-3 fold by T66K
BIC: no effect of T66A/I 
E92Q/G RAL: >5 fold by E92Q
EVG: >30 fold by E92Q, 10 fold by E92G
DTG: 1.5 fold by E92Q 
BIC: no effect of E92Q
E138K/A/T Usually occurs in combination with Q148 mutations. Alone: no 
reduction of INSTI-susceptibility
+Q148:
RAL: >100 fold 
EVG: >100 fold
DTG: 10 fold
G140S/A/c Usually occur in combination with Q148H/R/K. Alone: no 
reduction of RAL and DTG-susceptibility, 3-5 fold reduction of 
EVG-susceptibility.
+Q148:




RAL: 5-20 fold by Y143C and R, 5-10 fold by Y143K/S/G/A
EVG: no effect by Y143C and R
DTG: no effect by Y143C and R




S147G RAL: minimal effect
EVG: 5 fold
DTG: minimal effect













EVG: > 100 fold
DTG (or + E138K/T/A): 10 fold
BIC (or + E138K/T/A): 10 fold
Q148N: low-level EVG-resistance
N155H/S/T/D RAL: >10 fold
EVG: > 30 fold
DTG: reduced susceptibility in combination with other INSTI-
RAMs 
rare primary mutations
G118r Varying from no effect to 10 fold reduction to each of the 
INSTIs 
F121Y RAL: 5 fold
EVG: >10 fold 
DTG: no effect
P145S High-level EVG-resistance
Q146P EVG: 2-5 fold
r263K EVG: 6 fold
DTG: 2 fold
BIC: 2 fold








L74m/I/F Alone: minimal if any effect
+ any of the Primary resistance mutations: reduced 
susceptibility to all INSTIs
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An important mechanism to take into account, when cART is switched, is cross-resistance 
between different agents. Cross-resistance means that RAMs, which develop during use of a 
specific antiretroviral agent, also confer resistance to another antiretroviral agent of the same 
ART class. This is a common phenomenon for RAL and EVG for example. The consequence of 
development of cross-resistance is, that with the ‘loss’ of one treatment option, another treatment 
option is lost as well (e.g. loss of EVG in the case of development of a Q148K during RAL-use).
characteristics of clinical available integrase strand transfer inhibitors
At this moment, the INSTIs RAL, EVG, DTG, and BIC are widely available in clinic. 
Another INSTI, cabotegravir (CAB) has shown promising results in clinical phase 2 and 3 
studies. All have shown favorable clinical and virological properties. The individual INSTIs 
will be discussed below.
Raltegravir
Raltegravir (MK-0518, RAL) was the first clinical approved INSTI after its authorization in 






Synergistical reduction of RAL and EVG susceptibility
Q95K Alone: minimal if any effect 







S153Y/F EVG, DTG, and BIC: 2-3 fold
E157Q RAL: minimal effect
EVG: minimal effect
DTG: minimal effect
G163r/K Usually occurs in combination with other INSTI-RAMs, 
usually N155H
S230r EVG: > 2 fold
DTG: 2 fold
BIC: 2 fold
Table 3. Overview of integrase strand transfer inhibitor resistance associated mutations. Adapted from the 
Stanford University HIV Drug Resistance Database.72
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naive individuals, and it was combined with TDF plus FTC or 3TC, or with an optimized 
background regimen (OBR) in case of resistance against multiple antiretroviral classes. Its 
efficacy was high, AEs were comparable or lower, and development of RAMs occurred less 
frequent compared to regimens with two NRTIs with NNRTIs or PIs. For a summary of the 
results of the phase 2 and phase 3 studies on RAL-containing cART, see Table 4. 
RAL’s 95% inhibitory concentration effect (IC95) of HIV-replication is at 16 ng/mL. The 
time to peak plasma-concentration after oral administration is 0.5 to 1.3 hours. This peak 
is followed by a biphasic decline in plasma-concentration, with a half-life (t1/2 ) of 1 hour 
and 7–12 hours in the first and second phase respectively. With RAL 400mg twice daily, 
the steady state (where drug concentrations over time are constant due to nearly equal ab-
sorption and elimination) is reached after two days. In individuals receiving 400 mg twice 
daily, a mean viral load reduction after 10 days of 1.66 log10 c/ml was observed regardless 
of HIV-subtypes.73,80,82,83 RAL is primarily hepatically metabolized via uridine diphosphate 
glucuronosyltransferase (UGT) 1A1, and excreted in feces and urine.84 There is no interaction 
with cytochrome P450 enzymes including CYP3A4, hormonal contraceptives, the membrane 
transporter P-glycoprotein, and UGT enzymes. This dramatically reduces the drug-drug-
interaction risk.85 Only drugs that contain divalent cations (e.g. Mg2+ containing antacids) 
should be taken with caution due to their binding to INSTIs in the gastro-intestinal tract 
reducing absorption.86 In clinical trials, RAL was well tolerated; its most frequently reported 
AEs were gastrointestinal and neuropsychiatric, or increases in creatinine kinase (CK) and 
liver enzymes. Discontinuation rates of RAL for AEs were infrequent compared to placebo or 
EFV.74–81 Of note, RAL is not available in a single tablet regimen (STR), so cART-regimens 
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elvitegravir
Elvitegravir (GS-9137, EVG) was the second first-generation INSTI after FDA authorization 
in 2012. EVG/c has been investigated in phase 2 and phase 3 studies with cART-naive or 
INSTI-naive individuals. EVG/c’s efficacy was high, AEs were comparable or lower, and 
development of RAMs occurred less frequent compared to two NRTIs with NNRTIs or PI. 
For a summary of the results of the phase 2 and phase 3 studies on EVG/c-containing cART, 
see Table 5.
EVG/c was initially available with TDF/FTC as STR. In 2015, EVG/c/TAF/FTC became 
available as alternative STR, and this combination has the alleged advantage of less risk of 
renal deterioration. EVG/c’s IC95 is 45 ng/mL, and the time to peak plasma-concentration 
is 4.0 to 4.5 hours. T1/2 is approximately 9 hours. In individuals receiving 50 mg of EVG/c 
QD, the mean viral load reduction was 1.91log10 c/mL after 10 days, and EVG/c is equally 
active against all HIV subtypes.103–105 Besides CYP3A4, EVG/c is hepatically metabolized 
by UGT1A1 and UGT1A3, which leads to excretion of the majority of metabolites in faeces, 
and another small part in urine.103 The CYP3A4-inhibiting properties of COBI result in a risk 
on drug-drug-interactions between EVG/c-containing cART and a number of drug-classes, 
e.g. anticonvulsants, anticoagulants, direct acting antivirals, and statins.14 As with all INSTIs, 
drugs containing bivalent cations should be taken with caution. On the other hand, the pill-






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dolutegravir (S/GSK1349572, DTG) came available as second-generation INSTI in 2013. 
The distinction between first- and second-generation INSTIs is based on the risk of devel-
opment of INSTI-RAMs, which is lower in second generation INSTIs. This lower risk on 
RAMs is caused by changes in the structure of the INSTI, compared to the first genera-
tion: the zinc-binding component and peripheral structural elements differ from RAL’s and 
EVG’s.106 HIV develops RAMs compromising RAL and EVG/c efficacy relatively easily 
when used in INSTI-naive patients, and significant cross-resistance between these agents 
occurs. DTG as one of the second-generation INSTIs is less susceptible to the development 
of RAMs: INSTI-RAMs develop very infrequently in INSTI-naive patients, and DTG often 
remains active against RAL- or EVG/c-resistant viral strains.29,107,108 The phase 2 and 3 stud-
ies showed that DTG-containing cART had non-inferior and sometimes superior virological 
efficacy compared to NNRTI-, PI-, and RAL- and EVG-containing cART in INSTI-naive and 
INSTI-experienced patients with a low risk on development of RAMs. Furthermore, it has 
antiretroviral activity against RAL- and EVG- resistant viral strains, it has a favorable AE 
profile, and has a low risk on drug-drug-interactions. For an overview of the phase 2 and 3 
studies, see Table 6.
The time to peak plasma-concentration of DTG is 0.5 to 1.25 hours, and t1/2 is 13 to 15 
hours. The IC90 is 64 ng/mL. A steady-state is reached after five days.
122 In patients receiving 
the recommended 50mg dose once daily, plasma HIV-RNA decreased 2.46 log10 c/mL in 10 
days.109 Like the other INSTIs, DTG has good antiviral activity against HIV B- and non-B 
subtypes.123–125 DTG is metabolized by UGT1A1 and CYP3A4, and excreted in feces (~50%) 
and urine.126 Like RAL, there is a low risk on drug-drug-interactions, but cation-containing 
medication should be taken with caution. DTG’s inhibition of the renal organic cation trans-
porter 2 (OCT2) and MATE1 is of importance for drug-drug-interaction risks. These trans-
porters aid in drug clearance (e.g. metformin) and tubular creatinine transport. This results 
in serum creatinine increases, consequently decreasing the creatinine based estimation of the 
estimated glomerular filtration rate (eGFR). However, this does not reflect an actual decline in 
glomerular renal function.125,126 Despite the favorable data regarding AEs in the phase 2 and 3 
studies, there are rising concerns about the higher incidence of neuropsychiatric AEs in post 
marketing studies.125,127,128



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Bictegravir (GS-9883, BIC) is the fourth available INSTI belonging to the second-generation 
INSTIs. It was introduced in 2017. Like DTG, the phase 2 and 3 studies on BIC showed 
good antiretroviral activity in cART-naive and cART–experienced individuals. However, its 
efficacy in INSTI-experienced patients remains to be demonstrated. Besides, the AE profile 
is favorable, and the risk on drug-drug-interactions is low. Table 7 shows an overview of the 
clinical trials on BIC.
The time to peak plasma-concentration after oral administration of BIC is 1 to 3 hours, with 
a t1/2 of 16 to 22 hours, and a steady-state after 10 days. BIC has an IC95 of 162 ng/mL. It has 
antiviral activity against all HIV-subtypes. In individuals receiving 50 mg QD, HIV-RNA 
decreased mean 1.37Log10 after 11 days. BIC is metabolized by CYP3A4 and UGT1A1, and 
excreted in feces and urine. The risk on drug-drug-interactions is limited to inhibitors of both 
CYP3A4 and UGT1A1 (e.g. atazanavir) or inducers of CYP3A4 (e.g. rifampicin).129,135,136 
Medications containing bivalent cations should be taken with caution. An important advan-
tage of BIC above DTG and EVG/c is its absent effect on tubular creatinine clearance.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cabotegravir (GSK1265744, CAB) is an INSTI which has not yet been approved for treat-
ment of HIV. The unique property of CAB is that it can be administered orally or as injectable. 
The effectivity of CAB was evaluated in the LATTE-I and LATTE-II studies, see Table 8. For 
the randomized ATLAS and ATLAS-2M phase 3 studies on CAB, an oral CAB dosage of 30 
mg was chosen.
The time to peak plasma-concentration after parenteral administration of CAB 800 mg is 
6 days, and t1/2 is 40 days. CAB has an IC90 of 166 ng/mL. A steady-state is reached after 3 
months, when injections are given every 4 weeks.139,140 The time for oral CAB 30 mg to peak 
in plasma is 2 hours, and steady-state is reached after 14 days.141,142 CAB has antiretroviral 
activity against all HIV-subtypes, and a mean HIV-RNA reduction of 2.3Log10 is observed 
after 11 days of monotherapy at a dose of 30 mg QD.143,143 Metabolization of CAB is primar-
ily by UGT1A1 with excretion in feces and urine.141 The risk on drug-drug-interactions is 
low, but when given orally, CAB should be administered 2 hours before or 6 hours after 
medications containing bivalent cations. The genetic barrier of CAB against development of 
INSTI-RAMs is higher than RAL and EVG/c, but not as high as DTG’s and BIC’s.145
In conclusion, the class of INSTIs consists of agents with equal or superior antiretroviral ac-
tivity compared to NNRTIs and PIs. The second-generation INSTI have a high barrier against 
development of RAMs, a favorable AE-profile, and a low drug-drug-interactions risk. These 
properties make second-generation INSTIs potential candidates for simplification strategies, 
which will be studied in this thesis.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































General introduction and outline of the thesis 47
RIsks of InTegRase sTRand TRansfeR InHIbIToR conTaInIng 
combInaTIon anTIReTRoVIRal THeRaPy
Although treatment with antiretroviral therapy is life-saving for HIV-infected individuals, 
it is not without potential toxicity and risks. Initiation of cART in therapy-naive patients 
who are severely immunocompromised, may lead to an excessive immune response. This 
phenomenon is called the immune reconstitution inflammatory syndrome (IRIS) and can be 
associated with significant morbidity and in certain subgroups of patients also with increased 
mortality. Beside the risk for IRIS, which is limited to patients with a low CD4 T-lymphocyte 
count at initiation of cART, short and long-term side effects of cART can occur in all HIV-
infected patients. Both IRIS and direct cART-toxicities should be considered when initiating 
or switching cART. Below, these aspects will be discussed.
Immune reconstitution inflammatory syndrome
IRIS in HIV is a group of heterogeneous clinical symptoms, all caused by an excessive im-
mune response against antigens of opportunistic infections (OI). Two key mechanisms play 
a role in development of IRIS: i) a severe CD4 T-lymphocyte deficiency might lead to the 
presence of OIs, as well as an inadequate immune response against them, and ii) immune 
dysfunction. Studies suggest that a deficient CD4 T-lymphocyte function also leads to an 
impaired innate immunity (including antigen presenting cells like monocytes, neutrophils, 
and macrophages). This results in antigen accumulation, and cART-induced immune recov-
ery causes priming of innate immune cells and an excessive inflammatory response against 
antigens of OI. Second, although differences in antigen-specific T-lymphocyte responses have 
not been consistently detected between those who develop IRIS and those who do not, an 
imbalance of immune regulation by Th1- and Th2-lymphocytes may in part be responsible. 
Furthermore, patients who develop IRIS have higher levels of pro-inflammatory cytokines 
(IL-2, interferon-γ) and lower levels of anti-inflammatory cytokines (IL-10, IL-4).146–148 Two 
types of IRIS can be distinguished: paradoxical IRIS and unmasking IRIS. In paradoxical 
IRIS, an OI is diagnosed before cART-initiation. After cART-initiation, the clinical course of 
the OI first improves as a consequence of directed OI therapy. However, afterwards, a dete-
rioration in the clinical course occurs, with recurrence of signs and symptoms of the initial 
OI. This deterioration is considered secondary to restoration of the immune response, not 
failing OI treatment. In unmasking IRIS, an OI is not diagnosed before cART-initiation, often 
because there are no typical signs and symptoms of the OI as consequence of severe immune 
deficiency. After initiation of cART, a deterioration of the clinical course occurs, due to an OI 
which is only then diagnosed.148 Mortality rates up to 30% in central nerve system IRIS have 
been reported. Mortality and morbidity depend on the causative OI, and consequently the 
localization of IRIS and the severity of the disease.148,149 A conditio sine qua non for IRIS is 
a low CD4 T-lymphocyte count at the initiation of cART. Furthermore, treatment-associated 
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risk-factors are a steep decline in HIV-RNA and a fast increase of CD4 T-lymphocytes.150–152 
The use of INSTI-containing cART has been associated with a faster HIV-RNA decline and 
CD4 T-lymphocyte increase than PI- or NNRTI-containing cART.77,93,121 The low risk for 
drug-drug-interactions, their efficacy, and good safety profile make INSTIs good candidates 
for the treatment of severely immunocompromised AIDS patients with complex comorbidi-
ties. However this should be reconsidered when the IRIS-risk is increased in AIDS patients 
initiating INSTI-containing cART. Currently, adequate studies on the relationship between 
initiation of INSTI-containing cART and the risk for IRIS are lacking.
Toxicity of InsTI-containing caRT
More often than VF, cART-related toxicities are the main reason to discontinue cART. 
Side-effects also decrease adherence, one of the cornerstones of successful treatment of 
HIV.153,154 Toxicities can be related to drug classes, or to specific individual agents within 
these classes. Simplification of cART, using INSTIs, may help to overcome this important 
problem. However, when simplification to an antiretroviral regimen without (N)NRTIs is 
not possible, other strategies to overcome cART-toxicity may be helpful. Within the class of 
NRTIs, ABC is associated with a potentially lethal hypersensitivity reaction in individuals 
who have the HLA-B5701 allele (approximately 5% of the Caucasian population), but this 
risk has been eliminated by testing for HLA-B5701-positivity. Additionally, several large 
cohort studies found an association of ABC use and cardiovascular events particularly in 
patients at increased cardiovascular disease risk.155–157 TDF, another commonly used NRTI, 
sometimes causes renal toxicity. This is reflected by a progressive eGFR-decline or by proxi-
mal tubular dysfunction (PTD).158–160 TDF can also decrease bone mineral density and may 
result in an increased fracture risk, in particular in an ageing HIV-population.161,162 Since 
August 2016, TDF-related toxicity can be avoided by replacing it by TAF. TAF and TDF are 
different prodrugs of tenofovir. TAF is more stable in plasma than TDF, and it is hydrolyzed 
to tenofovir by cathepsin A in the CD4 T-lymphocytes, which leads to higher intracellular 
tenofovir-concentrations, and 90% lower plasma tenofovir-concentrations. This 90% lower 
overall exposure to tenofovir leads to less renal and bone exposure to tenofovir.163 Compa-
rable to HLA-B5701 screening for ABC hypersensitivity, screenings for the development of 
TDF-associated toxicity would be useful, as TDF is still commonly used in cART. Besides, 
TDF is used for pre-exposure prophylaxis (PrEP) for HIV-negative individuals as well, to 
prevent HIV-transmission. In the cellular DNA-metabolism, toxic by-products are produced. 
A group of toxic compounds of the cellular DNA-metabolism is the group of non-canonical 
nucleoside triphosphates (NTPs), and incorporation in the DNA leads to an increased risk on 
mutagenesis. NTPs could be removed by the ‘housekeeping-enzyme’ inosine triphosphatase 
(ITPase).164 Purines are the building blocks of DNA and RNA, and tenofovir and ABC are 
analogues of purines. Tenofovir is an adenine nucleotide analogue, and ABC is a guanine 
nucleotide analogue. Therefore, tenofovir and ABC might be potential substrates for ITPase. 
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Recently, a study showed a potential relationship between ITPase activity and toxicity caused 
by analogues of the purine metabolism. A decreased ITPase-activity showed to be protective 
against occurrence of TDF-associated AEs, while it was associated with an increase in ABC-
related AEs. The exact underlying mechanism for this finding has not been elucidated yet, 
but probably it can be explained by the fact that tenofovir is an adenine nucleotide analogue, 
wherease ABC is a guanine nucleotide analogue, which have different chemical structures. 
However, the AEs in this study were not specified, so the relationship between ITPase-activity 
and TDF-associated nephrotoxicity and bone-toxicity remains to be studied, as well as the 
potential of recovery of TDF-associated nephrotoxicity.165
Also other ART classes all have their specific toxicities. Within the class of NNRTIs, par-
ticularly EFV is associated with more neuropsychiatric events compared to other NNRTIs. 
Furthermore, the NNRTIs are associated with occurrence of rash and hepatitis. 166–169 PIs have 
gastrointestinal complaints and increases of serum lipids as their common side effects, and 
because they need to be combined with a strong CYP3A4 inhibitor, drug-drug-interactions 
are frequent.170,171 As discussed above, INSTIs are well tolerated, but there are some concerns 
about potential neuropsychiatric side effects of DTG. Also, CK increase is occasionally 
reported, and nausea is reported by some patients, in particular during the first weeks.127,172
An historical overview of toxicity developments of cART is studied by the Dutch ATHENA 
(AIDS Therapy Evaluation in The Netherlands) cohort study. Apart from showing the 
changes in first line cART preferences, the incidence of switching cART due to toxic-
ity almost halved from 26% in 1996-2000 to 14% in 2006-2010. Especially patients with 
stavudine-, didanosine, and AZT-based regimens had a high toxicity risk. Patients during 
1996-2000 usually switched due to gastrointestinal (36.2%), hepatological (15.2%), and 
hematological (10.1%) AE. In 2001-2005 gastrointestinal (24.9%), neuropsychiatric (14.9%), 
and hematological (12.9%) were the most reported AEs, and between 2006 and 2010, these 
were neuropsychiatric (30.7%), dermatological (16.6%), and gastrointestinal (15.3%) AEs.173 
Although these data did not include patients on INSTI-containing cART, the toxicity driven 
cART-discontinuations were obviously high. Reduction of cART-toxicity therefore remains 
an important research area, also in the era of INSTI-containing cART.
ouTlIne of THIs THesIs
The studies that will be described in chapter 2 to 8, and which resulted in this thesis, aim to 
evaluate the effectiveness and safety of new HIV treatment strategies with INSTIs, especially 
DTG, in HIV-1 infected individuals. Furthermore, several aspects of cART-toxicity with dual 
NRTI backbones in combination with an INSTI, PI, or NNRTI are evaluated. The ultimate 
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goal is a more individualized and patient-centered therapy by balancing virological and im-
munological efficacy with reduction of the risk of adverse events. This thesis focuses on three 
issues.
Part 1 focuses on the effects of a switch from triple cART to DTG as maintenance mono-
therapy. Given DTG’s high genetic barrier against resistance, the low potential for drug-
drug-interactions, and the favorable side-effects-profile, DTG could be a good candidate for 
monotherapy. The virological efficacy of DTG maintenance monotherapy compared to triple 
cART is investigated in chapter 2. chapter 3 describes resistance dynamics in the patients 
who experienced VF during DTG maintenance monotherapy, and chapter 4 studies clinical 
and virological factors which are associated with VF during DTG maintenance monotherapy. 
In chapter 5, the effects of a switch from cART to DTG maintenance monotherapy on 
metabolic markers are evaluated.
In part 2, the safety of initiating INSTI-containing cART in HIV late presenters with compro-
mised immunity on the risk of IRIS is discussed. In chapter 6, the hypothesis is tested that 
use of INSTI-containing cART as first line therapy in HIV late presenters is associated with 
an increased risk of development of IRIS.
Part 3 concentrates on aspects regarding safety of the NRTI backbone in INSTI, PI, or NNRTI 
containing cART and possibilities to further individualize HIV treatment. The association 
between ITPase activity and occurrence and recovery of renal toxicity in TDF-users is inves-
tigated in chapter 7. In chapter 8, the renal effects of a switch to TAF or ABC in patients 
with a TDF-associated eGFR-decline or PTD are studied.
Finally, chapter 9 provides a summary with a discussion of the study results and their impli-
cations for future directions.
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The high genetic barrier to resistance of dolutegravir (DTG) might allow for its use as 
maintenance monotherapy in patients with HIV. We investigated whether DTG monotherapy 
was non-inferior to combination antiretroviral therapy (cART) for maintaining virological 
suppression in HIV-1 patients successfully treated with cART.
methods
We did this open-label, phase 2, randomised non-inferiority trial at two medical centres in 
the Netherlands. Eligible patients (aged ≥ 18 years) were on cART, had been virologically 
suppressed (plasma HIV-RNA <50 c/mL) for at least 6 months, and had CD4-nadirs of 200 
cells/mm3 or higher, HIV-RNA zeniths of less than 100.000 c/mL, and no history of virologi-
cal failure (VF). Patients were randomly assigned (1:1) via a web-based block randomization 
method (variable block sizes of 4 and 6) to switch to dolutegravir monotherapy (50 mg once 
a day) either immediately or after a delay of 24 weeks of continued cART. Randomisation 
was stratified by HIV-RNA zenith (<50.000 c/mL or 50.000-99.999 c/mL). Investigators 
and patients were not masked to group allocation. The primary endpoint was the propor-
tion of patients with plasma HIV-RNA viral loads of less than 200 c/mL at week 24, with 
a non-inferiority margin of 12%. We did analyses in the on-treatment and intention-to-treat 
populations. This trial is registered with ClinicalTrials.gov, NCT02401828.
Results
Between March 10, 2015, and Feb 4, 2016, we randomly assigned 51 patients to the immedi-
ate switch group and 53 to the delayed switch group. One patient who received immediate 
monotherapy discontinued dolutegravir at week 12 because of disturbed sleep. At week 24, 
dolutegravir monotherapy was non-inferior to cART with plasma HIV-RNA loads of 200 
c/mL or higher observed in 2% (1/50) during immediate dolutegravir monotherapy and in 
0/53 patients in the delayed dolutegravir monotherapy group (difference 2%, exact 95% 
CI -5%,+12%). Of patients assigned to the delayed switch group, 47 of 53 patients (89%) 
switched to dolutegravir monotherapy at week 24, and two of them (4%) subsequently dis-
continued dolutegravir monotherapy because of headache (N=1) and disturbed sleep (N=1). 
Eight (8%) of the 95 patients who remained on dolutegravir monotherapy had VF; all had 
therapeutic DTG plasma-concentrations. In three of the eight patients, mutations associated 
with resistance were detected in the integrase gene. According to a predefined stopping rule, 
detection of these mutations led to premature study discontinuation.
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conclusions
Dolutegravir monotherapy was non-inferior to cART at 24 weeks. However VF continued to 
occur thereafter and led to dolutegravir resistance in three patients. Dolutegravir should not 
be used as maintenance monotherapy.
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InTRoducTIon
Combination antiretroviral therapy (cART) regimens containing the second-generation in-
tegrase inhibitor dolutegravir (DTG) showed equal or superior virological suppression rates 
compared with raltegravir, efavirenz, or darunavir containing cART in treatment of HIV-1 
infected adult patients.1 –3 This high virological efficacy, the favorable safety profile, and the 
high genetic resistance barrier of DTG has led to the recommendation of DTG-containing 
cART as first-line strategy in HIV treatment guidelines.4,5 Although existing cART regimens 
are effective, maintenance therapy with one or two drugs might have advantages, including 
reduced side-effects, pill burden, and costs. Various factors make DTG a suitable candidate 
for maintenance monotherapy: the development of resistance is rare in integrase inhibitor-
naive patients; the risk of drug-drug-interactions is low, the drug has a good tolerability, a 
once-daily dosing schedule, a small pill size, and a neutral effect on serum lipids.1,6,7 Previous 
studies have not shown monotherapy with protease inhibitors to be virologically non-inferior 
to cART, although virological failure (VF) during protease inhibitor monotherapy has not 
been associated with an increased incidence of resistance to protease inhibitors.8,9 However, 
in one study of virologically suppressed patients fulfilling strict criteria regarding HIV-RNA 
zenith (<100.000 c/mL) and CD4-nadir (>200 cells/mm3) protease inhibitor maintenance 
monotherapy was non-inferior to cART.10 We found DTG maintenance monotherapy to be 
promising in a retrospective observational study of five patients, although no control group 
was used.11 Therefore, we conducted the randomized DOMONO trial to evaluate whether a 
switch to DTG monotherapy would be non-inferior to continuation of cART in maintaining 
virological suppression in HIV-1 infected patients.
meTHods
study design and participants
We conducted this open-label, phase 2, randomized, non-inferiority trial in two university 
medical centres in the Netherlands: the Erasmus MC and the University Medical Center 
Groningen (UMCG). Eligible patients were HIV-1 infected adults, on cART and virologically 
suppressed (HIV-RNA <50 c/mL) for at least 6 months at the time of screening, with an HIV-
RNA zenith of less than 100.000 c/mL and a CD4-nadir of 200 cells/mm3 or higher. A previ-
ous HIV-RNA zenith of 100.000 c/mL or more was allowed if measured during an untreated 
acute HIV-infection. We excluded patients with a chronic hepatitis B virus (HBV) infection or 
without anti-HBs antibodies and not willing to undergo HBV vaccination. We also excluded 
subjects with previous VF on any cART or with any documented HIV-1 resistance with at 
least low-level resistance according to the Stanford HIV drug resistance database.12 Patients 
had to have a self-reported adherence of at least 95%. For a complete list of the inclusion 
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criteria and exclusion criteria, see Table 1 of the Supplementary Data. The study was ap-
proved by the Dutch competent authority and the Institutional Review Board of the Erasmus 
MC Rotterdam (NL51858.078.15). The study was done in accordance with Good Clinical 
Practice and the Helsinki Declaration. All participating subjects provided verbal and written 
informed consent in the language they could read (Dutch or English) before study procedures.
Randomisation and masking
We randomly assigned (1:1) eligible patients, via a web-based block randomization method 
(variable block sizes of 4 and 6) to switch to DTG monotherapy either immediately or after a 
delay of 24 weeks of continued cART (control). Randomization was stratified by HIV-RNA 
zenith (<50.000 c/mL or 50.000-99.999 c/mL). Because patients in the control group also 
switched to DTG monotherapy after 24 weeks, no randomized control group on cART was 
available after that timepoint. Therefore, we also collected data from a concurrent control 
group, which included eligible HIV-1 patients on cART who did not want to switch therapy. 
These patients remained in standard care for HIV-1, underwent no study procedures, and 
provided verbal consent for use of their clinical data for research purposes. Investigators and 
patients were not masked to group allocation.
study procedures
We prescreened patients by reviewing their files for the inclusion and exclusion criteria. Eli-
gible patients first received information about the study from their physician, and those who 
were interested in the study were referred to an investigator for a formal screening visit. We 
did clinical and laboratory assessments, including HIV-RNA, renal, urinary, and hepatic vari-
ables at weeks 0, 12, 24, 36, and 48. Additionally, HIV-RNA was also measured at weeks 4, 8, 
and 18 with the COBAS® ampliprep/COBAS®Taqman® HIV-1 v2 test (Roche diagnostics, 
Almere, The Netherlands). We defined VF as two consecutive HIV-RNA measurements of 
200 c/mL or higher. We contacted all patients with an HIV-RNA of 200 c/mL or higher and 
retested them immediately to confirm the result. Patients with confirmed VF were taken off 
DTG monotherapy and restarted cART. We did Sanger sequence analysis of the integrase 
gene with in-house primers from EDTA-containing plasma that had been collected at the 
time of VF and before cART initiation, and we measured DTG plasma-concentrationsin these 
plasma samples. We contacted patients with a viral load above 20 but below 200 copies per 
mL and instructed them to take DTG with food to increase absorption, we then measured their 
plasma DTG levels concentrations in stored plasma to check for therapy compliance. After 
48 weeks on DTG monotherapy, patients with viral loads less than 50 c/mL could choose 
to continue DTG monotherapy with plasma HIV-RNA measurements every 12 weeks, or to 
reinitiate cART. We informed patients that continuation of DTG monotherapy would be off 
label use and documented their consent again in the patient file. To protect the safety of the 
study participants, predefined stopping were the detection of resistance associated mutations 
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(RAMs) in the integrase gene in more than two patients during the study and failure of DTG 
monotherapy in more than 20 patients at any time during the study.
outcomes
The primary endpoint of the study was the proportion of patients with plasma HIV-RNA 
of less than 200 c/mL at 24 weeks in the on-treatment (OT) population. The OT population 
consisted of all patients initiating DTG monotherapy except for those who discontinued 
DTG because of an adverse event while virologically suppressed at the time of DTG dis-
continuation. The intention to treat population (ITT) consisted of all patients who started 
DTG monotherapy. A temporary increase of the plasma HIV-RNA from less than 50 c/mL to 
50-200 c/mL is not infrequent during cART. Furthermore, given the relatively small sample 
size of a phase 2 study, we expected only one to three patients with VF in each group. As such, 
the use of a cutoff of 50 c/mL could have led to inappropriate statistical conclusions about 
non-inferiority; therefore, we used 200 c/mL as cutoff for the primary analysis. Predefined 
secondary endpoints reported herein were the proportion of patients in the OT-population 
with plasma HIV-RNA of less than 50 c/mL at week 24, the proportion of patients in the entire 
population on DTG monotherapy after 48 weeks with plasma HIV-RNA less than 200 c/mL, 
the proportion of patients in the ITT population with plasma HIV-RNA of less than 200 c/
mL at week 24, and the number and type of RAMs in the integrase gene of patients with con-
firmed HIV-RNA of 200 c/mL or higher at any time-point during DTG monotherapy. Other 
predefined secondary endpoints included bone, renal, and inflammatory markers and will be 
reported elsewhere. We registered adverse events according to the Common Terminology 
Criteria for Adverse Events version 4.0. Because of the study design, it would not have been 
fair to compare the groups for all adverse events that were not considered drug related (eg. 
Bronchitis, headache, diarrhea) because patients in the immediate switch group were seen or 
contacted seven times during the first 24 weeks, whereas patients in the delayed switch group 
were seen or contacted only twice. Therefore, adverse events would have been more frequent 
in the immediate switch group.
statistical analyses
The sample size calculation was based on a non-inferiority design comparing DTG monother-
apy with cART. Assuming virological suppression (HIV-RNA < 200 c/mL) in 95% of patients 
in both groups (Pa=Pb=0.95), a non-inferiority margin of 12%, 80% power and a one-sided 
confidence interval of 97.5% (α=0.025), a sample size of 104 patients would be needed. For 
the primary endpoint, we calculated 95% exact confidence intervals for differences in propor-
tions.13 In a post-hoc analysis, we used Fisher’s Exact test to compare virological suppression 
rates between the entire population on DTG monotherapy at study discontinuation and the 
concurrent control population. We did all analyses with the statistical software package R 
(version 3.3.1). This trial is registered with ClinicalTrials.gov (NCT02401828).
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ResulTs
Between March 10, 2015 and February 4, 2016, we randomly assigned 104 patients to receive 
immediate (N=51) or delayed (N=53) DTG monotherapy (Figure 1). Baseline characteristics 
were similar between the groups (Table 1).
For our concurrent control group, we recruited 152 consecutive patients who had chosen not 
to participate in the DOMONO study. Patients in this group had to have been available for 
follow-up for at least one year and have a viral load measurement available between 44 and 
56 weeks after they were initially considered eligible for the DOMONO study. The entire 
OT-population receiving DTG monotherapy consisted of 95 patients (N=50 in the immediate 
switch group and N=45 in the delayed switch group, Figure 1). The OT-population assessed 
for the week 24 primary endpoint consisted of 50 patients in the immediate switch group and 







male sex, N(%) 47 (92) 48 (91)
Age, median (Q1,Q3) 46 (37,56) 45 (40,51)
Transmission route, mSm, N(%) 41 (80) 41 (77)
Ethnicity, caucasian, N(%) 44 (86) 42 (79)
cArT regimen before switch, N(%)
NNrTI + 2 NrTI 41 (80) 43 (81)
PI + 2 NrTI 2 (4) 1 (2)
INI + 2 NrTI 7 (14) 9 (17)
other 1 (2) 0 (0)
receiving an STr, N(%) 32 (63) 41 (77)
on TDF before switch, N(%) 44 (86) 45 (85)
median (Q1,Q3) time on cArT, months 35 (24,61) 43 (25,68)
median (Q1,Q3) time suppressed on cArT, months 31 (20,54) 39 (21,60)
median (Q1,Q3) HIV-rNA zenith, copies per mL 29.300 (14.800-76.900) 44.877 (16.100-63.100)
median (Q1,Q3) cD4 T-lymphocyte nadir, cells/mm3 320 (250-490) 380 (285-515)
Table 1. Baseline characteristics of the immediate DTG monotherapy and the delayed DTG monothera-
py group. MSM=Men having Sex with Men, NNRTI=Non-Nucleoside Reverse Transcriptase Inhibitor, 
NRTI=Nucleoside Reverse Transcriptase Inhibitor, PI=Protease Inhibitor, INI=Integrase Inhibitor, STR=Single 
Tablet Regimen,TDF=Tenofovir Disoproxil Fumarate, cART= combination AntiRetroviral Therapy.
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At 24 weeks, the proportions of patients with plasma HIV-RNA of 200 c/mL or higher were 2% 
(1/50) in the immediate DTG monotherapy group and 0% in the delayed DTG monotherapy 
group (difference 2%, exact 95% confidence interval -5% to +12%; Figure 2). The plasma 
HIV-RNA of the single patient in the immediate DTG monotherapy group who had VF was 
71.600 c/mL, detected at week 4 of DTG monotherapy. The patient had a self-reported adher-
Patients on cART
N=1700
Patients eligible for participation
N=360
Not willing to participate
N=256






















No switch to DTG 
monotherapy
N=6
Moved away from Rotterdam 
(1)
Withdrew informed consent 
(1)
Non-compliance (2)













Figure 1. Patient disposition in the study. cART=combination AntiRetroviral Therapy, ITT=intention to treat, 
OT=on treatment, DTG=dolutegravir, AE=adverse event.
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ence of 100%, an adequate DTG plasma-concentration (1.29 mg/mL, measured 14 hours after 
intake), and the integrase sequence showed no DTG-RAMs. However, we realize that even 
a 100% correct pill count and adequate plasma-concentrations at preplanned blood draws 
cannot exclude temporary incompliance with certainty. The patient reinitiated cART with 
single-tablet tenofovir disoproxil fumarate, emtricitabine, and rilpivirine, and had a plasma 
HIV-RNA of less than 50 c/mL within 12 weeks after cART reinitiation (Table 2). After 24 
weeks of treatment, 8% (4/50) of the patients in the immediate DTG monotherapy group 
and 0% of the 53 patients in the delayed switch group had a plasma HIV-RNA of 50 c/mL or 
higher (difference 8%, exact 95% confidence interval [-1%, +20%]). In the ITT-analysis at 
week 24, 4% (2/51) of patients in the immediate switch group and no patients in the delayed 
switch group had a plasma HIV-RNA of 200 c/mL or higher (difference 4%, exact 95% 
confidence interval [-4%, 15%]).
Of the 95 patients on DTG monotherapy in the OT-population, 78 (82%) had reached the 
week 48 endpoint when we decided to discontinue the study early in agreement with the pre-
defined stopping criteria. At that time, eight patients on DTG monotherapy had VF; N=6 in 
the immediate switch group and N=2 in the delayed switch group (Table 2). Two patients had 
VF before week 24 and the other six had VF after week 24 (Table 2). In all patients with VF, 
DTG plasma-concentrations were therapeutic and self-reported adherence was greater than 
95% (Table 2). In patient 7, a period of suboptimal DTG plasma-concentrations might have 
occurred because of gastro-enteritis. Integrase sequencing was successful in six patients who 
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L Figure 2. Percentages of virological suppression at 
week 24: on treatment analysis. * 1/51 patients dis-
continued DTG monotherapy at week 12 (HIV-RNA 
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with VF at week 60 and the N155H in the patient with VF at week 72. In the patient with 
VF at week 30, the S230R mutation was detected (Table 2). Integrase sequencing of stored 
plasma collected before initiation of cART showed that these mutations were not present at 
that time. After the decision was made to stop the study prematurely, all participants were 
contacted by the study team and were instructed to reinitiate their previous cART regimen. 
Another informed option was addition of two nucleoside reverse transcriptase inhibitors to 
DTG, if the subject’s plasma HIV-RNA was still undetectable.
We followed up 83 (the five patients who had VF before week 48 plus 78 other patients) of 
the 95 patients who received DTG monotherapy for at least 48 weeks. When the study was 
discontinued, 77 (93%) of these patients had an HIV-RNA of less than 200 c/mL, and the last 
HIV-RNA to be measured was less than 50 c/mL in 76 patients (92%). In only one of the eight 
patients who had VF, the VF was preceded by two consecutive HIV viral loads of greater than 
50 c/mL. Therefore, in the seven other patients with a confirmed viral load of 200 c/mL or 
higher, VF occurred suddenly with no preceding low-level viral replication.
Of the 61 patients who completed the 48 week 48 follow-up and were virologically suppressed 
at that time, 59 chose to continue DTG monotherapy, whereas two preferred to switch back 
to cART. One patient had VF at week 48 and also reinitiated cART. Sixteen patients were 
in the 44-48 week follow-up window when the study was discontinued, and therefore, were 
not given the option to continue DTG monotherapy. We measured HIV-RNA measurements 
every 12 weeks thereafter, and the median follow-up in the 59 patients who continued DTG 
monotherapy was 64 weeks. In two of them, VF occurred after 48 weeks; the remaining 57 
patients had HIV-RNA of less than 50 c/mL.
DTG monotherapy was inferior to cART in a post-hoc analysis comparing the overall viro-
logical suppression rate (<200 c/mL) in patients in the concurrent control group (149/152, 
98%) with that in the 95 patients on DTG monotherapy in the OT-population at week 48 




























Figure 3. Percentages of virological suppression in entire study population: on treatment analysis. *8/53 pa-
tients in the delayed DTG monotherapy group did not switch to DTG monotherapy and were long enough to 
follow-up for inclusion in the OT-analysis, which brings the total number of patients on DTG to 95.
dIscussIon
DTG monotherapy was non-inferior to cART in maintaining virological suppression for 
24 weeks, with VF recorded in only one patient in the group of patients who switched im-
mediately to DTG monotherapy and in no patient in the delayed switch group. No RAMs 
in the integrase gene were detected in the virus of the one patient with VF at week 24, and 
viral replication in this patient was re-suppressed soon after reinitiation of cART. Despite 
these promising results, VF was observed in seven additional patients after week 24, which 
led to virological suppression rate in 92% of patients at the time of study discontinuation. 
This result was statistically inferior to the 98% suppression rate observed in the concurrent 
control group. Because all eight patients with VF achieved re-suppression of the plasma viral 
load soon after reinitiation of cART, this observation alone would not contraindicate DTG 
monotherapy. However, the results of integrase sequencing at the time of VF clearly showed 
that DTG monotherapy cannot replace cART, even in patients with a CD4-nadir above 200 
cells/mm3 and an HIV-RNA zenith of less than 100.000 c/mL. In two of the six patients 
in whom integrase sequencing was successful, well defined resistance associated mutations 
were detected at position 263 and 155 of the integrase gene. Additionally, in one patient, a 
change at position 230 was observed, which is an accessory mutation that has been previously 
described in combination with other RAMs in the integrase gene of patients with VF on 
raltegravir or elvitegravir.14 The three mutations could not be detected in viral RNA from 
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stored plasma collected before initiation of cART. The presence of acquired RAMs in the 
integrase gene in three of the 95 patients was inconsistent with the results from three phase 3 
studies on DTG-containing cART.2,3,15 No mutations associated with decreased susceptibility 
to integrase inhibitors was observed in any of the 1067 treatment-naive patients who started 
DTG-containing cART in the phase 3 FLAMINGO, SINGLE, and SPRING-2 studies.2,3,15 
Given the development of RAMs in the integrase gene of more than two patients on DTG 
monotherapy in our study, with the potential for cross-resistance to other available and future 
integrase inhibitors, one of the stopping rules was met and the study was terminated. Devel-
opment of RAMs in the integrase gene has been extremely rare in patients on DTG previously 
untreated with integrase inhibitors and with a history of VF on other antiretroviral drugs; in 
the SAILING study, such mutations were observed in only two of 354 patients during the first 
48 weeks of follow-up.1 More recently, five small observational studies found that VF led 
to the development of a new RAM in the integrase gene in five of 118 patients treated with 
DTG monotherapy.11,16–19 However, these studies were done in patients undergoing routine 
clinical care with non-standardized monitoring and without formal approval from any ethics 
committee.
We documented good self-reported adherence and therapeutic DTG plasma-concentrations 
in all patients who had VF on DTG monotherapy, and no other patient-related causes (such 
as intercurrent diseases or use of concomitant medications) could be identified as a possible 
causes of VF. However, we realize that self-reported adherence is not always reliable. The 
development of VF, with or without RAMs, is possibly the result of ongoing (low-level) 
viral replication. Therefore, DTG monotherapy seems to be insufficiently potent, and its 
genetic barrier to resistance insufficient, to decrease viral replication in all tissues to levels 
low enough to avoid development of resistance. Notably, in two of the three patients who 
developed resistance, we observed VF after plasma HIV-RNA levels had been below 20 c/
mL at eight consecutive visits, and was therefore not preceded by documented viral replica-
tion. We can only speculate about the possible mechanisms of virological escape in the three 
patients in whom known RAMs in the integrase gene were not detected and therapeutic DTG 
plasma-concentrations were measured. Possibly, resistance to integrase inhibitors can also 
develop outside the integrase gene as recently described in in vitro experiments.20 A similar 
outcome has been described in the context of resistance against protease inhibitors, wherein 
mutations at the protease cleavage side were involved in protease inhibitor resistance.21
Several hypotheses might explain the occurrence of VF in our cohort. First, the decision 
to start cART in patients was more often based on a decreasing CD4 T-lymphocyte count 
than on HIV-RNA or other factors. Therefore, HIV-RNA measurements from a time close to 
cART initiation were not available in four of the eight patients who had VF, meaning that the 
HIV-RNA zeniths in these patients just before cART intiation might have been greater than 
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100.000 c/mL. The multivariate analysis in the PROTEA-trial showed the relevance of this 
criterion, darunavir monotherapy was inferior to darunavir-containing cART in patients with 
an HIV-RNA of greater than 100.000 c/mL before initiation of cART.22 However, in all three 
patients with RAMs in the DOMONO study, the HIV RNA plasma viral load on the day of 
cART initiation had been measured and was less than 100.000 c/mL in all patients, and was 
as low as 20.000 c/mL in one patient.
Besides the HIV-RNAzenith, an estimation of the size of the viral reservoir might be a more 
reliable predictor of VF during maintenance therapy with fewer drugs.23 In the MONOI-trial, 
a higher baseline total HIV-DNA copy number was associated with virological rebound on 
darunavir monotherapy.24 If this finding can be confirmed in future studies of maintenance 
therapy with fewer drugs, quantification of HIV-DNA as marker of the viral reservoir has the 
clear advantage as marker of the reservoir that it can be measured before simplification of 
cART.
Whether other mechanisms, such as differences in drug-concentrations between plasma and 
sanctuary sites (eg lymphoid tissue), are involved in failure of DTG maintenance mono-
therapy remains unknown.25,26 We examined other more obvious factors that could have been 
associated with VF during DTG monotherapy, such as time on type of cART, CD4-nadir, and 
height of the peak viral load before initiation of cART. Given the strict inclusion and exclu-
sion criteria of the study, and the few events, it is not surprising that the eight patients with 
VF were similar to the 87 other patients with regard to these factors (p>0.05 for all). Another 
explanation for the development of mutations associated with resistance to DTG could be 
that patients had archived replication-competent viruses with pre-existing RAMs, and that 
this virus was reactivated during monotherapy. Finally, although plasma-concentrations 
of DTG were therapeutic in all patients, intermittent non-adherence could not be entirely 
excluded. However, even if patients had been intermittently non-adherent, a switch to DTG 
monotherapy in those who had been virologically suppressed on cART for years led to an 
unacceptable number of patients with VF and RAMs in the integrase.
Our study has several limitations. First, the study was small and was only intended to be a 
proof-of-concept study before designing a larger study with a smaller non-inferiority margin 
and a primary endpoint of 50 c/mL. Second, the 24 week delayed-switch design has been used 
in most randomized studies of treatment switches and has the advantage that study results are 
available 48 weeks after the last patient is randomized. However, several patients in this study 
had VF between week 24 and 48. Therefore, future switch studies should use week 48, rather 
than week 24, as the primary endpoint. Finally, given the very strict inclusion and exclusion 
criteria, the external validity is limited to a small proportion of HIV patients in care.
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In conclusion, although DTG monotherapy was non-inferior to cART after 24 weeks, it led 
to VF in a relatively high number of patients during longer-term follow-up. Moreover, three 
patients with VF developed resistance to integrase inhibitors. DTG should therefore not be 
used as maintenance monotherapy.
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suPPlemenTaRy daTa cHaPTeR 2
Inclusion criteria Exclusion criteria
Documented HIV-1 positive by ELISA or Western Blot 
or Plasma HIV-RNA >1000 copies/mL
Previous virological failure on any cART
18 years or older Patients without anti-HBs antibodies who are not 
willing to undergo hepatitis B vaccination
HIV-RNA <50 copies/mL for >24 weeks Subjects positive for hepatitis B at screening (HBsAg+)
Historical baseline HIV-RNA plasma load <100.000 
copies/mL. A HIV-RNA plasma load >100.000 
copies/mL is allowed, if measured during an acute 
HIV infection. Acute means within 6 months after a 
negative HIV-1 test or during the documentation of an 
incomplete HIV-1 Western Blot antibody-test.
No record of the historical baseline plasma viral load 
available
CD4-T-lyphocyte nadir ≥200 cells per μL Subjects with concomitant CDC-C opportunistic 
infections within 90 days of screening
Not on strong UGT1A1 or CYP3A4 inducing agents as 
stated in DTG SPC
Subjects with history of allergy to INI
General medication is not interfering with trial 
procedures (on investigators’ discretion)
Subjects with creatinine clearance <50 ml/min 
according to CKD-EPI
Females should have no plans of becoming pregnant 
during the next 18 months after baseline visit
Subjects with hepatic impairment of at least Child-Pugh 
B
Exposure to experimental drug or experimental HIV-1 
vaccine within 90 days of start DTG
Screening ALT >5x ULN or ALT >3x ULN and 
bilirubin >2x ULN
Patient planning or hoping to conceive a child or 
become pregnant during the study
Patients who cannot take DTG 2 hours before or 6 hours 
after antacids, calciumcarbonate, or iron supplements
Table S1. Overview of inclusion criteria and exclusion criteria.
reasons for not switching to DTG 
monotherapy
Total (N=6)
moved away from treating hospital, N=1 Moved away from treating hospital, so was not able to comply 
with all scheduled study procedures.
Withdrew informed consent, N=1 Was satisfied with cART-regimen, so did not want to switch 
from cART to DTG monotherapy
other, N=2 No show at scheduled visit for switch from cART to DTG 
monotherapy and following visits
Physician’s decision, N=2 Diagnosis and surgery for prostate carcinoma during the 
cART period.
In need of use of Mg2+, so drug-drug interactions with DTG 
expected.
Table S2. Reasons for not switching to DTG monotherapy
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Figure S3. Kaplan Meier curve of percentages virological suppression (HIV-RNA < 200 copies/mL) in the 




HIV-1 resistance dynamics in patients with virological 
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A high genetic barrier to resistance to the integrase strand transfer inhibitor (INSTI) dolute-
gravir has been reported in vitro and in vivo. We describe the dynamics of INSTI resistance 
associated mutations (INSTI-RAMs) and mutations in the 3’-polypurine tract (3’-PPT) in 
relation to virological failure (VF) observed in the randomized dolutegravir as maintenance 
monotherapy study (DOMONO, NCT02401828).
methods
From ten patients with VF, plasma samples were collected before the start of cART and 
during VF, and were used to generate Sanger sequences of integrase, the 5’ terminal bases of 
the 3’ long terminal repeat (LTR), and the 3’-PPT.
Results
Median HIV-RNA at VF was 3,490 (interquartile range 1.440-4.990) c/mL. INSTI-RAMs 
were detected in 4 patients (S230R, R263K, N155H, and E92Q+N155H), no INSTI-RAMs 
were detected in 4 patients, and sequencing of the integrase gene was unsuccessful in 2 
patients. The time to VF ranged from 4 to 72 weeks. In 1 patient, mutations developed in the 
highly conserved 3’-PPT. No changes in the terminal bases of the 3’-LTR were observed.
conclusions
The genetic barrier to resistance is too low to justify dolutegravir maintenance monotherapy, 
because single INSTI-RAMs are sufficient to cause VF. The large variation in time to VF sug-
gests that stochastic reactivation of a pre-existing provirus containing a single INSTI-RAM 
is the mechanism for failure. Changes in the 3’-PPT point to a new dolutegravir resistance 
mechanism in vivo.
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InTRoducTIon
The second-generation integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) seems 
to have a high genetic barrier to resistance in vitro, with significant loss of replication capac-
ity in viruses with INSTI resistance associated mutations (RAMs) compared with wildtype 
viruses.1,2 The high genetic barrier to DTG resistance when administered as DTG-containing 
cART is already demonstrated in vivo: no RAMs associated with decreased DTG susceptibil-
ity were observed in any of the 1067 treatment-naive patients who initiated DTG-containing 
cART in pivotal phase 3 studies.3–5 In treatment-experienced but INSTI-naive patients taking 
a DTG-containing cART-regimen, virological failure (VF) with development of INSTI-
RAMs is rare.6,7 Furthermore, mutations selected by the first generation INSTI raltegravir 
(RAL) and elvitegravir (EVG) might have limited impact on DTG susceptibility, enabling 
successful treatment with DTG-containing cART in a large proportion of patients who previ-
ously developed VF during use of RAL- or EVG-containing cART, although dosing DTG 
twice daily is necessary for certain INSTI-RAMs.7–11
Given the high genetic barrier to DTG resistance and other favorable properties of DTG, such 
as few drug-drug-interactions, few adverse events, and a low pill-burden, we hypothesized that 
DTG could be used as monotherapy to maintain viral suppression in HIV-1 infected adults with 
long-term virological suppression during cART. More recently, DTG maintenance monotherapy 
has been investigated in small, retrospective, observational studies and case series, which showed 
high rates of virological suppression without emergence of INSTI-RAMs in INSTI-naive pa-
tients. These studies included a total of 118 patients, in five of whom VF led to development 
of INSTI-RAMs, but all five were INSTI-experienced or had treatment-compliance issues. 
Also, these studies were done in routine clinical care and without standardized monitoring and 
ethics committee approval.12–16 As these results lacked a control arm, we conducted the ran-
domized, controlled Dolutegravir as Maintenance Monotherapy for HIV-1 study (DOMONO, 
NCT02401828) and showed that DTG maintenance monotherapy in HIV-1 infected patients led 
to a higher rate of VF (8/95, 8%) compared with patients who continued cART (3/152, 2%).17
Since INSTI-RAMs in the integrase gene are rarely detected in patients with VF to DTG-
containing cART,5,6 novel DTG resistance pathways outside of the integrase gene may ex-
ist. Experiments with purified integrase enzyme and long terminal repeat (LTR) duplexes 
showed that mutations in the four terminal bases of the LTR could confer INSTI resistance.18 
Furthermore, in vitro DTG resistance selection experiments showed that mutations in the 
3’-polypurine tract (3’PPT) confer high-level resistance to RAL, EVG, and DTG.19 Both 
resistance pathways have not been reported yet in HIV-infected individuals. Here, we de-
scribe the dynamics of resistance-associated mutations in the integrase gene and the 3’-PPT 




Patients with VF during DTG maintenance monotherapy were included from two studies 
performed in the outpatient clinic of the Erasmus University Medical Center (Rotterdam, 
The Netherlands) and the University Medical Center Groningen (Groningen, the Nether-
lands). The first group of patients consisted of participants in the DOMONO main study. 
The most important inclusion criteria were a CD4 T-lymphocyte nadir above 200 cells/mm3, 
an HIV-RNA zenith below 100.000 c/mL (except when measured during the acute phase of 
infection), and no previous VF and/or any documented RAMs, according to The Stanford 
HIV Drug Resistance Database.20 The second group of patients consisted of participants in 
the DOMONO pilot study. This pilot study had the same inclusion and exclusion criteria as 
the main study, with the exception that patients with a CD4 T-lymphocyte nadir below 200 
cells/mm3 were included.
study procedures
HIV-1 RNA in plasma was quantified with the COBAS® ampliprep/COBAS®Taqman® 
HIV-1 v2 test (Roche diagnostics, Almere, The Netherlands). VF was defined as a confirmed 
plasma HIV-RNA level above 200 c/mL. Adherence was defined as the percentage self-
reported adherence. DTG plasma-concentrations at the moment of VF were determined and 
interpreted according to the Therapeutic Drug Monitoring protocol of Radboud University 
Medical Center (Nijmegen, the Netherlands).21 In all patients, Sanger sequences covering 
the integrase gene, and the 3’-PPT and the four 5’ terminal bases of the 3’-LTR in the nef 
gene were determined using stored plasma samples with detectable HIV-RNA before patients 
started on cART (baseline samples) and in plasma samples at time of VF during treatment 
with DTG monotherapy. For nef amplification, RNA was isolated with the High Pure Viral 
RNA kit (Roche, #11858882001), according to the manufacturer’s instructions. Of 60 µL of 
eluted RNA, 12.5 µL was used for complementary DNA synthesis, using 50 pmol oligo dT 
primer (20T+TRAAG, Eurogentec) and superscript IV (ThermoFisher) with the following 
polymerase chain reaction (PCR) conditions: 5 minutes at 30°C, 2 hours at 50°C, and 10 
minutes 80°C. After RNase H inactivation (by incubation for 20 minutes at 37°C and 15 
minutes at 70°C), 5 µL of complementary DNA was used for PCR analysis. Primers were 
as follows: HXB2-8343for//T (or C): AGAGTTAGGCAGGGATAT(C)TCACC and HXB2-
9632rev: GCACTCAAGGCAAGCTTTATTGAGGCT. PCR conditions were as follows: 2 
minutes at 94°C and 40 cycles of 10 seconds 94°C, 30 seconds at 60°C, 1 minute at 68°C, and 
10 minutes at 68°C (extension). PCR samples were separated on 1% agarose, and bands were 
cut and extracted with QIAEX II gel extraction kit (Qiagen) before sequencing. For integrase 
sequencing, nucleic acids were extracted using MPLC (Roche) after ultracentrifugation of 1.5 
mL ethylenediaminetetraacid-plasma at 26.000xg for 1 hour at 4°C. Subsequently, the HIV-1 
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integrase gene was amplified with the OneStep RT-PCR kit (Qiagen, Venlo, The Netherlands) 
and 20 pmol of the primers described in supplementary Table 1, according to manufacturer’s 
protocol, using the following thermal profile: 30 minutes at 50°C, 15 minutes at 95°C, and 
25 cycles of 1 minute at 95°C, 1 minute at 55°C, 2 minutes at 72°C, and 10 minutes at 72°C. 
Nnested PCR was then performed with the HotStar HiFidelity Polymerase kit according to 
the manufacturer’s protocol and the following thermal profile: 5 minutes at 95°C and 30 
cycles of 15 seconds at 94°C, 1 minute at 50°C, 2 minutes at 72°C and 10 minutes at 72°C. 
One microliter of the amplicon was sequenced using the BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and 5 pmol of 
sequencing primers described in supplementary Table 1. The sequenced PCR products were 
purified using Performa DTR V3 purification plate (Edgebio, Sopachem, Ochten, The Neth-
erlands) and analyzed on an ABI 3130XL sequencer (Applied Biosystems). The sequence 
data were analyzed using a Sequence Navigator software sequencer (Applied Biosystems) 
and SeqMan v10.1.2 (DNASTAR, Madison,WI). Resulting HIV-1 integrase sequences were 
further analyzed using the Stanford database to check for known drug RAMs, and baseline 
sequences were compared to rebound sequences using BioEdit, v7.2.0.20
ethical considerations
The DOMONO main study and its pilot study were approved by the Dutch Medical Ethics 
Committee and were performed in accordance with good clinical practice and the Helsinki 
Declaration. All participating subjects provided verbal and written informed consent before 
study procedures.
ResulTs
Patient population and baseline characteristics
Eight of 95 participants of the DOMONO main study had VF. Of the four participants of the 
DOMONO pilot study, two had VF. In total, 10 patients experienced VF during DTG main-
tenance monotherapy. Baseline characteristics at entry of DTG maintenance monotherapy 
study are listed in Table 1. All participants were male with a median age of 46 years and 
were infected with HIV-1 subtype B. The median HIV-RNA zenith was 29.750 c/mL and 
the median CD4 T-lymphocyte nadir was 235 cells/mm3. In three patients (patient 5, 9, 10) 
cART was initiated within a year after the HIV-diagnosis. Nine of the participants with VF 
were INSTI-naive, whereas one patient (patient 3) was previously treated successfully with 
RAL-containing cART and DTG-containing cART. The median duration of plasma HIV-
RNA suppression (defined as a plasma HIV-RNA lower than 50 c/mL) during cART (ie. 
before initiation of DTG maintenance monotherapy) was 61 months.
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characteristics of virological failure during dTg maintenance monotherapy
Clinical and virological characteristics at the moment of VF are shown in Table 2 and 3. 
Median HIV-RNA (IQR) at VF was 3.490 (1.440-4.990) c/mL. Interestingly, the time to VF 
after the start of DTG maintenance monotherapy varied considerably, with patient 4 already 
experiencing VF at week 4 and patient 7 experiencing VF at week 72. The median time to VF 
was 33 weeks. Self-reported adherence was more than 95%, and DTG plasma-concentrations 
during DTG maintenance monotherapy were therapeutic (i.e. above 0.50 mg/L) in all patients 
at time of VF. Two patients received co-medication (patient 3: oxazepam, buprenorphine/nal-
oxone, fluticasone, quetiapine, levomepromazine, and prednisolone; patient 5: simvastatin, 
acetylsalicylic acid, tolbutamid, perindopril, and metoprolol), but no drug-drug-interactions 
were detected. No INSTI-RAMs were detected in the samples obtained from patients before 
they started therapy. At the moment of VF detection, INSTI-RAMs were detected in patients 
2, 5, 7, and 9, whereas no known INSTI-RAMs were detected in patients 1, 4, 8, and 10; 
integrase gene sequencing was unsuccessful in patients 3 and 6 owing to low plasma HIV-
RNA levels of 1.440 and 678 c/mL respectively. Single INSTI-RAMs were detected in three 
patients: S230R (in patient 2), R263K (in patient 5), and N155H (in patient 7). In patient 9, 
the combination of E92Q and N155H was detected. Figure 1 shows the courses of plasma 
HIV-RNA levels and the INSTI-RAMs detected during treatment with DTG maintenance 
monotherapy.
Patients (N=10)
male sex, N (%) 10 (100)
Age, years, median (Q1,Q3) 46 (39,52)
mode of transmission, N (%)
 mSm 7 (70)
 HSX 2 (20)
 other 1 (10)
Ethnicity, N (%)
 caucasian 7 (70)
 caribbean/Surinam 3 (30)
Time on cArT, median (Q1, Q3), months 71 (47, 104)
Time suppressed on cArT, median (Q1, Q3), months 61 (41, 101)
INSTI-naive, N (%) 9 (90)
HIV-1 subtype B, N (%) 10 (100)
HIV-rNA zenith, median (Q1, Q3), c/ml 29.750 (18.250, 66.625)
cD4 T-lymphocyte nadir, median (Q1, Q3), cells/mm3 235 (183, 300)
Table 1. Baseline characteristics of patients with virological failure on dolutegravir maintenance monotherapy. 
DTG=dolutegravir, MSM=men having sex with men, HSX=heterosexual, cART=combination antiretroviral 
therapy, INSTI=integrase strand transfer inhibitor.












































































































































































































































































































































































































































































































































































































































































































































































































































































































Additional changes in integrase at VF 
compared to baseline
4 Main 4 No No VI32I, LS45L, T112A
6 Main 12
below limit of 
detection
No -
10 Pilot 24 No No IV72V, LI101I
1 Main 30 No No
A10D, D11E, N17S, L45Q, I50M, T111K, 
A112T, T124S, I135V, KR211K, I220L
2 Main 30 S230R No EV13E, LV45L
3 Main 36
below limit of 
detection
No -
9 Pilot 42 E92Q, N155H No T112I
8 Main 48 No No G24GNDS, R111RK, A124AT, A229D, S283G
5 Main 60 R263K No
ED10E, ED11E, L45I, F121FV, RK231K, 
LF234L
7 Main 72 N155H No D41G, T111A, S119R, N155H, M208I
Table 3. Virological characteristics and mutations in the integrase gene of HIV from patients with VF on 
dolutegravir maintenance monotherapy. VF=Virological Failure, DTG=dolutegravir, INSTI-RAMs=Integrase 
Strand Transfer Inhibitor – Resistance Associated Mutations. *In weeks after start DTG maintenance mono-
therapy.










































Figure 1. Overview of the course of the plasma HIV-RNA and INSTI-RAMs in all patients with VF. The dotted 
line represents the limit of quantification of plasma HIV-RNA (20 copy/mL). -=sequencing of integrase gene 
unsuccessful due to low plasma HIV-RNA level.
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To investigate the role of an alternative resistance mechanism, we sequenced the nef gene, 
including the 3’-PPT and four 5’ terminal bases of the 3’-LTR, because mutations in these 
sites can confer resistance to INSTIs.18,19 No mutations were observed in the four 5’ terminal 
bases of the 3’-LTR at baseline or at VF in any of the patients. In 9 of 10 patients, we did 
not detect changes in the 3’-PPT located in the nef gene. However, in patient 10, who did 
not develop INSTI-RAMs in the integrase gene, the wildtype G-stretch of the 3’-PPT was 
observed at baseline (i.e. GGGGGG), but at VF two changes were detected, i.e. GGGAGc 
(Figure 2).
Figure 2. Changes in the G-stretch of the 3’-PPT in patient 10 at VF and course of plasma HIV-
RNA. NVP=nevirapine, TDF=tenofovir disoproxil fumarate, FTC=emtricitabine, RPV=rilpivirine, 
DTG=dolutegravir. DTG-10-2007 is the sequence generated from HIV-RNA in plasma prior to cART ini-
tiation. DTG-10-2016 is the sequence generated from HIV-RNA in plasma at VF during DTG maintenance 
monotherapy. HXB2 is the sequence from the HXB2 reference strain.
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Virological response after restart of caRT
At the moment of confirmed VF, DTG maintenance monotherapy was stopped, and all 
patients restarted their previous cART regimen. The patients responded well to cART reinitia-
tion, including the patient who restarted with dolutegravir, emtricitabine, and tenofovir. In all 
patients, plasma HIV-RNA levels declined to lower than 20 c/mL and remained lower than 20 
c/mL for a mean of 39.7 weeks of follow-up.
dIscussIon
In the DOMONO study, we recently showed that a higher proportion of patients treated with 
DTG maintenance monotherapy experienced VF, compared with patients who continued to 
receive cART.17 In addition, 50% (2/4) of participants in the subsequent DOMONO pilot 
study, in which patients had a CD4 T-lymphocyte nadir of lower than 200 cells/mm3, had VF. 
The same observation was previously made during protease inhibitor maintenance mono-
therapy.22 Moreover, of the ten patients with VF in the main study and pilot study combined, 
we observed the emergence of INSTI-RAMs in four INSTI-naive patients: N155H (in patient 
7), E92Q + N155H (in patient 9), R263K (in patient 5), and S230R (in patient 2). These results 
are in contrast with findings of observational cohorts, in which VF during DTG maintenance 
monotherapy often occurred in INSTI-experienced patients, in patients with previous VF dur-
ing INSTI-containing therapy, and/or in patients with suboptimal adherence.12–16 Only Blanco 
et al are reporting VF with emergence of INSTI-RAMs in INSTI-naive patients.23 Emergence 
of the R263K mutation has previously been observed in the SAILING study in treatment-
experienced, INSTI-naive patients who experienced VF on DTG-containing cART6,24, and in 
the VIKING study, the N155H mutation emerged in patients with HIV resistant to RAL and/
or EVG, who were treated with DTG-containing cART.11,25 Furthermore, emergence of the 
N155H and E92Q+N155H was noted in the retrospective, observational Redomo-study in pa-
tients with VF on DTG maintenance monotherapy.23 To our best knowledge, the S230R muta-
tion has been described previously in one patient experiencing VF during DTG-containing 
cART.26 Interestingly, development of the S230R mutation was observed in 1 of 5 HIV-1 
infected humanized mice treated with DTG monotherapy. However, in that study, the S230R 
mutation was detected in combination with E138K, G140S, Q148H and N155H.27 In vitro, 
the N155H, N155H + E92Q and the R263K mutation caused 1-2-, 2.5-, and 2-4-fold changes 
in the IC50 of DTG and conferred only low-level resistance to DTG.
9,28,29 Pham et al. charac-
terized the S230R substitution and showed that it resulted in a 4-fold change in IC50 of DTG 
in tissue culture resulting in low level resistance to DTG.30 When combining these results 
with our observations in vivo, it appears that single INSTI-RAMs that result in a relatively 
small fold increase in the IC50 of DTG are sufficient to cause VF in patients receiving DTG 
maintenance monotherapy. In our study, plasma HIV-RNA levels were relatively low in eight 
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of the ten patients who experienced VF (lower than 1000 c/mL) compared with their pre-
cART HIV-RNA zenith. This suggests that DTG still exhibited partial antiretroviral activity. 
It should be noted that our patients received DTG 50 mg once daily and that treatment with 
higher doses of DTG may be sufficient to overcome this partial resistance and fully suppress 
replication of these viruses.11
In four patients with VF, no known INSTI-RAMs were detected (patient 1, 4, 8, and 10). For 
these patients, we compared the pre-cART integrase sequence with the integrase sequence 
during VF and found amino acid changes at the following positions: E10, E11, S17, S24, 
V32, L45, M50, I72, L101, K111, T112, T124, I135, K211, I220, D229, and S283. Mutations 
at these positions occur at frequencies of more than 1% in INSTI-naive patients.31 These 
mutations have not been shown to increase the IC50 of DTG in vitro,
31-33 although we cannot 
exclude that certain combinations of these mutations result in a decreased susceptibility to 
DTG. VF could also be explained by therapy non-adherence, but this seems unlikely because 
only therapy-adherent patients with no history of VF were included in our study, and DTG 
plasma-concentrations were therapeutic at the time of VF.
To find an explanation for VF, we searched for mutations outside of the integrase gene that 
may confer INSTI resistance in all ten patients. Therefore, we sequenced the 5’ terminal 
bases of the U3 region of the LTR (i.e. ACTG), which are the substrate for integrase in the 
integration process.18 Dicker et al showed with purified integrase enzymes and LTR duplexes 
that certain mutations in the four terminal bases of the LTR led to decreased binding of INSTI 
to integrase, while the strand-transfer activity of integrase remained relatively intact.18 These 
mutations have not been reported in HIV culture experiments or in vivo. In this study, we did 
not detect changes in the ACTG motif of the 3’-LTR in patients with VF.
Simultaneously, we sequenced the 3’-PPT region adjacent to the 3’-LTR, because mutations 
in this region have been linked to INSTI resistance. 19 Malet et al recently showed in in vitro 
HIV culture experiments involving high doses of DTG that mutations located in the nef gene 
led to INSTI resistance.19 The AàC mutation located 6 nucleotides upstream of the 3’-PPT 
motif in combination with four changes in the G-stretch of the 3’-PPT motif (GGGGGG 
à GcAGTdel), conferred high level resistance to DTG, RAL, and EVG. In our study, we 
detected mutations in the G-stretch of the 3’-PPT in the virus from patient 10 that were not 
present at baseline (GGGGGG à GGGAGc). Interestingly, a high DTG plasma-concentration 
was detected during VF in this patient, and the mutations in 3’-PPT described by Malet et 
al were also selected using high DTG concentrations in vitro. In addition, no known INSTI-
RAMs in the integrase gene were detected in this patient.
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The 3’-PPT is more than 99.9% conserved among HIV-1 sequences in the Los Alamos da-
tabase, as it serves as hybridization site for the RNA primer for plus-strand DNA synthesis 
during reverse transcription. Removal of these RNA primers is pivotal because it defines the 
end of the linear proviral DNA for integration.34 The GGGGGG à GGGAGC mutations in 
the 3’-PPT observed in patient 10 result in a glycine to alanine change in the Nef protein, 
and the mutations in the 3’-PPT described by Malet et al result in a truncated Nef protein. It 
seems unlikely, however, that the Nef protein plays a role in INSTI resistance, since there is 
hardly data that the Nef protein plays any role in the proviral integration process and because 
a previous study reported full susceptibility to RAL of Nef-deficient HIV.35 The terminal 
200–250 base pairs of each proviral DNA end are the primary protein binding sites of the 
HIV intasome.36,37 Since the 3’-PPT in the unintegrated linear proviral DNA intermediate is 
located approximately 9000 base pairs from the 5’-LTR and approximately 800 base pairs 
from the end of the 3’-LTR, it is unlikely that the 3’-PPT interacts with the HIV intasome.
Notwithstanding the findings above, the 3’-PPT plays a major role in defining the proviral 
DNA end of the 5’-LTR. Previous studies on the reverse transcription process showed that 
mutations in the G-stretch of the 3’-PPT can lead to incomplete removal of the 3’-PPT RNA 
primer by RNAse H or to an alternative starting point for plus-strand DNA synthesis.34,38-40 
Both scenarios would lead to an altered end of the unintegrated linear proviral DNA interme-
diate at the 5’-LTR site. In addition, production of viral particles from unintegrated proviral 
DNA has been proposed. In patient 10, we observed the emergence of different mutations in 
the 3’-PPT, compared with the virus described by Malet et al. This indicates that other muta-
tions in 3’-PPT may also cause INSTI resistance. However, experiments with site-directed 
mutants are needed to prove that the GGGGGG à GGGAGC mutations in 3’-PPT indeed 
cause INSTI resistance. In addition, further studies are needed to unravel the mechanism of 
INSTI resistance caused by mutations in 3’-PPT.
Still, for three patients we could not find a cause for virological failure. Of note is patient 4 
who had adequate plasma DTG levels and already failed four weeks after start of DTG main-
tenance monotherapy with a plasma HIV-RNA level of 71.600 c/mL. Ultra-deep sequencing 
of plasma HIV-1 RNA or proviral DNA in peripheral blood mononuclear cells during VF 
might show minority variants that harbor RAMs in integrase or 3’-PPT, which could partially 
explain VF. Unfortunately, samples needed for these analyses were not available. VF in 
these patients might also be explained by yet another novel resistance pathway, which would 
require whole-virus genome sequencing at baseline and during VF, and phenotyping of the 
emerged mutations with site-directed mutants. In addition, VF in these patients could be 
explained by replication of HIV in sanctuary sites in which DTG does not penetrate with 
subsequent spillover of HIV to peripheral blood.
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The origin of the viruses detected during VF in this study is currently unknown. These viruses 
might originate from ongoing low level replication in sanctuary sites during cART that are 
not detectable in plasma. However, Joos et al showed that after patients with long-term viro-
logical suppression (plasma HIV-1 RNA lower than 50 c/mL) stopping cART, the rebound 
viruses detected in plasma originate from reactivation of latently infected cells instead of 
viral lineages that continuously replicate at low levels.41 Reactivation of HIV from latently 
infected cells is a stochastic process which occurs on average every 5–8 days, and depends 
on the size of the replication competent viral reservoir. This may also explain why two of the 
four patients who had a CD4 T-lymphocyte nadir lower than 200 cells/mm3 and were included 
in the DOMONO pilot study, went on to have VF. Indeed, a low CD4 T-lymphocyte nadir is 
correlated with a larger viral reservoir.42,43 Owing to the error-prone nature of HIV replication, 
minority populations with drug resistant mutants harboring single resistance mutations are 
most likely generated before therapy is initiated and persist in the proviral archive.44,45 We 
hypothesize that the viruses detected during VF in this study originate from stochastic reac-
tivation of a single cell harboring a provirus with a preexisting INSTI-RAMs. Reactivation 
of wild type virus from latently infected cells will not result in further rounds of replication, 
because these viruses are inhibited by DTG. However, reactivation of a virus carrying a single 
INSTI-RAM is not fully inhibited by DTG and further rounds of replication will lead to 
detectable HIV-RNA levels in plasma. This hypothesis is supported by the large variation 
observed in the timing to failure due to stochastic nature of reactivation of proviruses carrying 
a single INSTI-RAM.
In conclusion, the genetic barrier to DTG resistance is too low to justify DTG maintenance 
monotherapy, even in treatment-adherent patients with a relatively low HIV-RNA zenith 
and high CD4 T-lymphocyte nadir. The exact mechanism of VF in patients with long-term 
virological suppression who switch to DTG maintenance monotherapy is currently unclear, 
but we propose stochastic reactivation of a single cell harboring a provirus with a pre-existing 
INSTI-RAM as mechanism for VF. Mutations in the G-stretch of the 3-PPT region might 
confer an alternative DTG resistance pathway.
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suPPlemenTaRy daTa cHaPTeR 3
Primer Sequence (5’-3’)
Position according to 
HXB2*
 Primers outer PcR
5’INoutF1 ggAATCATTCAAgCACAACCAgA 4059-4081
3’INoutR2 TGTATGCAGACCCCAATATGTT 5262-5241










Table S1. Primers for integrase sequencing. * Genbank accession no. K034550.
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Predictors of virological failure in HIV-1 infected 
patients switching to dolutegravir maintenance 
monotherapy.
I.E.A. Wijting, S.L. Rutsaert, C. Rokx, D.M. Burger, A. Verbon, J.J.A. van Kampen, 





The Dolutegravir Maintenance Monotherapy for HIV-1 (DOMONO; NCT02401828) study 
showed that maintenance monotherapy with dolutegravir (DTG) is associated with virologi-
cal failure (VF) and leads to DTG resistance, and as a result should not be used. However, 
data on clinical and virological factors associated with VF during DTG monotherapy are 
lacking. We identified factors associated with VF during DTG monotherapy.
methods
A randomized trial was carried out in which patients on combination antiretroviral therapy 
(cART) with an HIV-1 RNA zenith <100.000 c/mL, a CD4 T-lymphocyte nadir ≥200 cells/
mm3, who had never experienced VF, switched to DTG monotherapy. Clinical and virological 
factors were compared between patients with and without VF, using univariable analyses.
Results
Eight of the 95 patients developed VF during DTG monotherapy. A total of 78 participants 
had reached week 48 when the study was discontinued. The median (IQR) CD4 T-lymphocyte 
nadir was lower in patients with VF than in patients without VF (260 (223-320) cells/mm3 
versus 380 (290-520) cells/mm3, respectively, p=0.011). Patients with VF had a longer time 
between HIV-diagnosis and cART initiation than those without VF (49 (27-64) versus 15 
(1-38) months, respectively, p=0.015). The median total peripheral blood mononuclear cells 
(PBMC) HIV-DNA copy number (min, max) PBMCs was higher in patients with VF than 
in those without VF (417 (85-4151) versus 147 (16-4132) copies/106 PBMCs, respectively, 
p=0.022).
conclusions
A lower CD4 T-lymphocyte nadir, a longer time between HIV diagnosis and cART initiation, 
and a higher HIV-DNA copy number at the time of DTG monotherapy initiation were associ-
ated with VF. While there clearly is no future role for DTG monotherapy, ongoing and future 
studies on the efficacy of maintenance dual therapy (e.g. DTG with lamivudine) may have to 
take these variables into account in their study design and analysis.
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InTRoducTIon
Dolutegravir (DTG) based combination antiretroviral therapy (cART) is one of the pre-
ferred treatment options in current guidelines for HIV-1 treatment. Given the high genetic 
barrier to resistance of DTG maintenance monotherapy based on previously determined in 
vitro data,1–5 we studied its efficacy in the Dolutegravir Monotherapy for HIV (DOMONO, 
NCT02401828) study.6 In the DOMONO study, 95 virologically suppressed patients on 
cART, selected on strict criteria regarding CD4 T-lymphocyte nadir and HIV-RNA zenith, 
started DTG monotherapy. The study was discontinued prematurely, because virological 
failure (VF) was observed in eight patients, of whom three had integrase inhibitor resistance 
associated mutations.6–8 Previous studies on protease inhibitor (PI) maintenance monotherapy 
identified time on cART, drug adherence during monotherapy, the presence of very low-level 
viremia (plasma HIV-RNA less than 50 c/mL) at baseline, and CD4 T-lymphocyte nadir as 
predictors for failure.9,10 Additionally, the peripheral blood mononuclear cell (PBMC) HIV-
DNA copy number was associated with the risk of VF in the MONOI study and PROTEA 
study.9,11 Predictors of VF during integrase inhibitor monotherapy have not been described. 
Here we determined which clinical and virological factors are associated with VF during 
DTG monotherapy.
meTHods
The DOMONO study was a randomized clinical non-inferiority trial. Participants provided 
written informed consent, and the study was approved by the ethics committee (METC 
Erasmus MC, MEC2015-043) and performed in accordance with the Helsinki Declaration. 
Details can be found elsewhere, but in brief, 95 patients, who were virologically supressed on 
cART, had never failed any antiretroviral regimen, had a CD4 T-lymphocyte nadir of at least 
200 cells/mm3 and an HIV-RNA zenith lower than 100.000 c/mL, consented to switch from 
cART to DTG monotherapy.6 The primary outcome of this study was virological suppression 
at week 24 during DTG monotherapy, and we defined VF as a confirmed plasma HIV-RNA 
of more than 200 c/mL. Clinical and virological factors were compared between patients with 
and without VF using unpaired T-tests, Mann Whitney U Tests, and Fisher’s exact tests, when 
applicable. As a consequence of the relatively low number of patients with VF at the time 
when the study was discontinued, a multivariable analysis could not be performed. Factors 
included were as follows: age, sex, the pre-cART HIV-RNA zenith and CD4 T-lymphocyte 
nadir, the CD4 T-lymphocyte count at the start of DTG monotherapy, and the time between 
HIV diagnosis and cART initiation. Other evaluated factors were the type of cART-regimen 
before switch to DTG monotherapy (non-nucleoside reverse transcriptase inhibitor versus 
PI- versus integrase strand transfer inhibitor-containing cART), the time on cART, whether 
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the patient had a detectable viral load at the start of DTG monotherapy (defined as a plasma 
HIV viral load of more than 20 c/mL or a detectable HIV-RNA but lower than 20 c/mL), DTG 
plasma-concentration, and the total HIV-DNA copy number in PBMCs at the start of DTG 
monotherapy. Total HIV-DNA quantification was performed by droplet digital PCR (ddPCR), 
as described elsewhere, and could be done on 77 patients (eight patients with VF and 69 
without VF) from whom PBMC had been successfully harvested.12–14
ResulTs
Seventy-eight of the 95 participants had reached the week 48 endpoint when the study was 
discontinued prematurely in accordance with one of the predefined stopping rules. At the time 
of study discontinuation, VF had been observed in eight patients. Median (IQR) follow up 
duration was 59 (48-71) weeks and for 17 patients, including five with VF, the follow-up was 
shorter than 48 weeks. The characteristics of the patients with and without VF are described 
in Table 1.
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no VF during DTG 
monotherapy
(N=87)




Age, years, mean (SD) 47 (11.0) 47 (11.2) 0.891 (UTT)
male sex, N (%) 80 (92) 8 (100) 1.00 (FET)
HIV rNA zenith, copies/mL 37000 (12950,65625) 27350 (17750,64325) 0.973 (MWU)
Viremia at start DTG*, N (%) 10 (11.5) 2 (25.0) 0.266 (FET)
HIV DNA, copies/106 PBmcs 147 (69,338) 417 (181,837) 0.022 (MWU)
Log10 HIV DNA/106 PBmcs, mean (SD) 2.16 (0.53) 2.57 (0.40) 0.037 (UTT)
cD4 T-lymphocyte nadir, cells/mm3 380 (290,520) 260 (223,320) 0.011 (MWU)
cD4 T-lymphocyte count at start DTG, cells/
mm3
650 (540,825) 830 (573,1030) 0.153 (MWU)
cD4:cD8-ratio at start DTG 1.05 (0.74,1.50) 1.41 (0.74,2.00) 0.507 (MWU)
c-reactive protein at start DTG, mg/L 1.20 (0.40,2.70) 1.45 (0.73,3.08) 0.673 (MWU)
DTG plasma-concentration, mg/L 1.65 (1.23,3.75) 1.70 (1.05,2.40) 0.308 (MWU)
DTG plasma-concentration, % deviation from 
population average
12.9 (-43.2,55.2) 10.9 (-27.6,45.5) 0.879 (MWU)
cArT before DTG, N(%)
 NNrTI 69 (79.3) 7 (87.5) 0.783 (CST)
 PI 4 (4.6) 0 (0)
 INI 14 (16.1) 1 (12.5)
Time between HIV-diagnosis and start cArT, 
months
15 (1,38) 49 (27,64) 0.015 (MWU)
Time suppressed on cArT, months 31 (20,54) 57 (28,94) 0.104 (MWU)
Table 1. Baseline characteristics of patients with and without VF during DTG maintenance monotherapy, 
including p-values resulting from univariate analysis. Data documented as median (Q1,Q3), unless stat-
ed otherwise, DTG=dolutegravir, VF=virological failure, SD=standard deviation, UTT=unpaired T-test, 
FET=Fisher’s Exact test, MWU=Mann Whitney U test, * residual viremia is defined as HIV-RNA detectable 
but < 20 c/mL or > 20 c/mL, PBMC=peripheral blood mononuclear cells, cART=combination antiretroviral 
therapy, NNRTI=non-nucleoside reverse transcriptase inhibitor, PI=protease inhibitor, INI=integrase inhibitor, 
CST=Chi Square test.
Per study protocol, the median HIV-RNA zenith was low and the median CD4 T-lymphocyte 
nadir was relatively high with a minimum of 200 cells/mm³. The median (IQR) CD4 T-
lymphocyte nadir was significantly lower in the patients with VF at 260 (223-320) cells/mm3 
than in those without VF (380 (290-520) cells/mm3, p=0.011). The median time between 
HIV-diagnosis and cART initiation was longer in patients with VF: 49 (27-64) months versus 
15 (1-38) months for patients without VF on monotherapy (p=0.015). At the start of DTG 
monotherapy, no significant differences were observed between patients with and without VF 
regarding the number of patients with a detectable palsma HIV-RNA, the CD4 T-lymphocyte 
count, CD4:CD8-ratio or the C-reactive protein (CRP) concentration. In contrast, the median 
(min-max) total HIV-DNA copy number in PBMCs at the time of DTG monotherapy initia-
tion differed significantly between both groups: 147 (16-4132) versus 417 (85-4151) copies 
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per 106 PBMCs respectively (p=0.022). DTG plasma levels were adequate (i.e. > 0.1 mg/L) 
in all patients with VF and no difference in median (min-max) DTG plasma-concentrations 
was observed between the patients with VF and 20 randomly selected patients without VF: 
1.70 (0.70-2.90) mg/L versus 1.65 (0.70-4.50) mg/L. See Figure 1 for boxplots of CD4 T-
lymphocyte nadir, time between HIV diagnosis and start cART, total HIV-DNA copy number 
in PBMCs, and DTG plasma-concentrations in patients without and with VF.

























































































































Figure 1. Distributions of time between HIV-diagnosis and start cART (a), CD4 T-lymphocyte nadir (b), total 
HIV-DNA in PBMCs (c), and DTG plasma-concentration (d) in patients without and with VF during DTG 
maintenance monotherapy. cART=combination antiRetroviral therapy, PBMC=peripheral blood mononuclear 
cell, DTG=dolutegravir.
dIscussIon
In the DOMONO study, we clearly showed that DTG maintenance monotherapy is associated 
with VF and the development of DTG resistance, and it should not be used as maintenance 
monotherapy. In the current study we evaluated potential predictors of VF during integrase 
inhibitor monotherapy. We showed that a higher level of cell-associated total HIV-DNA copy 
number at start of monotherapy, a lower CD4 T-lymphocyte nadir, and a longer time between 
HIV-diagnosis and start cART were significantly associated with VF. A lower CD4 T-lympho-
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cyte nadir and a higher level of cell-associated HIV-DNA copy number have previously also 
been described as risk factors for virological failure during PI monotherapy.9–11 In contrast, 
none of the following ten factors were associated with VF during DTG monotherapy: gender, 
age, CD4 T-lymphocyte count, CRP, CD4:CD8-ratio, the type of the cART-regimen, whether 
the patient had detectable plasma HIV-RNA (all at the time of DTG monotherapy initiation), 
DTG plasma-concentrations during monotherapy, the duration of viral suppression on cART, 
and the HIV-RNA zenith before DTG monotherapy initiation. Also, no differences were 
observed regarding plasma viral load detectability in the 12 months preceding DTG mono-
therapy initiation: three of 87 patients without VF versus zero of eight patients with VF had 
HIV-RNA more than 20 c/mL in the 12 months preceding the switch to DTG monotherapy.
Various PI monotherapy studies identified suboptimal adherence as a risk factor for VF.9,15,16 
We were unable to analyze adherence as a predictor of VF, because the inclusion and exclu-
sion criteria of the study led to the selection of a very therapy-adherent study population: no 
history of VF on any previous cART regimen, a self-reported adherence during DTG mono-
therapy of more than 95%, and therapeutic DTG plasma-concentrations in all patients with 
and without VF. DTG plasma-concentrations were adequate in both groups and there was no 
significant difference in DTG plasma-concentrations between patients with and without VF, 
which consistent with previous studies which did not identify lower PI plasma-concentrations 
as a risk factor for VF in patients receiving PI monotherapy.16,17 It must be noted that drug 
level measurement was only performed at single time-points, so the possibility of temporary 
non-adherence between study visits cannot be ruled out.
The limiting factor of this study is the relatively small number of patients who experienced 
VF in comparison to the previously mentioned PI studies. Even if we had considered an iso-
lated and unconfirmed viral load of more than 50 c/mL as VF (as observed in 14 patients), the 
number of VF would have been too small to enable a multivariate analysis to be performed. 
Therefore, we were not able to assess whether CD4 T-lymphocyte nadir, time between HIV-
diagnosis and start cART, and cell-associated HIV-DNA copy number are independent risk 
factors for VF during DTG maintenance monotherapy. Actually, CD4 T-lymphocyte nadir, 
time between HIV-diagnosis and start cART, and cell-associated HIV-DNA levels could very 
well be correlated. Indeed, Boulassel et al previously showed the inverse relationship between 
CD4 T-lymphocyte nadir and cell-associated HIV-DNA levels18, and longer time between 
HIV-diagnosis and start cART is associated with higher cell-associated HIV-DNA levels.19 
This implies that the size of the viral reservoir is probably the most important determinant of 
VF, as the cell-associated total HIV-DNA level is a measure for the size of the viral reservoir 
in virologically suppressed patients. Reactivation of HIV from latently infected cells is a 
stochastic process, which occurs on average every five to eight days, and depends on the size 
of the replication competent viral reservoir.20 Our observation that a higher HIV-DNA level 
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is associated with VF is in agreement with stochastic reactivation of pre-existing provirus 
harboring a single integrase inhibitor mutation. It would have been useful to provide data on 
the size of the reservoir at the time of VF. Unfortunately, we did not collect PBMCs at the 
time of VF and therefore, we are not able to provide these data.
In conclusion, a longer time between HIV diagnosis and cART initiation, a lower CD4 T-
lymphocyte nadir, and a higher total HIV-DNA copy number increased the risk of VF during 
DTG monotherapy. While there clearly is no future role for DTG monotherapy, ongoing and 
future studies on the efficacy of maintenance dual therapy (e.g. DTG with lamivudine) should 
take these variables into account in their study design and analysis.
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Since the introduction of combination antiretroviral therapy (cART) to treat HIV-infection, 
an immense number of lives have been saved. However, this lifesaving treatment comes at 
a cost in a substantial number of individuals due to adverse events (AE), high pill-burdens, 
drug-drug-interactions, or lack of efficacy with the subsequent emergence of resistant viruses. 
It remains difficult to define the optimal cART regimen due to large interclass ART differ-
ences and, more importantly, to align them per individual clinical situation. Therefore, the 
central aim of this thesis is to evaluate the efficacy and safety of existing and new cART 
strategies, with a focus on integrase strand transfer inhibitors (INSTI), which could help to 
tailor antiretroviral regimens to the need of individual patients. The discussion of this thesis 
is divided in three parts. The first part describes the efficacy of a maintenance monotherapy 
simplification strategy with the second-generation INSTI dolutegravir (DTG), the second 
part is on the safety of INSTI initiation in the most vulnerable HIV population, and the third 
part further focuses on cART related toxicities and potential solutions. In this last part of the 
thesis, the clinical relevance of these findings is summarized (also in Dutch).
THe Role of doluTegRaVIR In sImPlIfIed anTIReTRoVIRal 
RegImens
Simplification of triple cART might have advantages, including reduction of AEs, pill burden, 
and drug-drug-interactions, and cost-effectiveness. DTG has a high virological efficacy and 
a high genetic barrier to resistance. Even in patients with previous treatment failure, DTG 
often remains active.1–5 The good virological properties, combined with a low risk on AEs and 
DDI, made DTG an ideal candidate to be studied as maintenance monotherapy simplification 
strategy in HIV patients.
dolutegravir maintenance monotherapy
In the randomized clinical non-inferiority DOlutegravir maintenance MONOtherapy for 
HIV-1 infected adults (DOMONO) study, presented in chapter 2, the aim was to prove that 
simplification to DTG maintenance monotherapy was non-inferior to cART. This strategy 
turned out to be of no clinical use, despite formal non-inferiority at the week 24 primary 
endpoint, since in total eight patients had virological failure (VF) on monotherapy and none 
in the control group continuing cART. Three of the eight patients also acquired mutations 
associated with resistance (RAM) in the integrase gene, which is in sharp contrast to the 
absence of any mutated virus in patients on DTG in the published phase 3 trials. The study 
was therefore prematurely terminated, with the conclusion that DTG should not be used as 
maintenance monotherapy.6 Five observational studies of DTG monotherapy in 118 patients 
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in total were conducted. Of note, they were all conducted prior to DOMONO and without 
report of ethical committee approval in the manuscripts. Interestingly, no VF with acquisition 
of resistance associated mutations (RAM) was found in patients who were never treated with 
INSTIs before and who did not have a history of VF.7–11 Other randomized studies confirmed 
the DOMONO results, however. The DOLAM-study in 91 patients included a simplification 
DTG maintenance monotherapy arm and compared this to cART and DTG dual therapy with 
lamivudine (3TC). Two patients on DTG monotherapy had VF, both with clinically signifi-
cant emerging RAMs (S147G/Q148R/N155H and E138K/G140S/N155H), compared to one 
patient on DTG/3TC without RAM in the integrase gene.12,13 Also, the MONCAY-study had 
seven patients with VF, including two with RAMs in the integrase gene, compromising clinical 
management (S147G/N155H and R263K) among a total of 78 patients on DTG monotherapy. 
A plasma HIV-RNA load between 0 and 20 copies/mL (c/mL) and low CD4 T-lymphocyte 
counts seemed to predict VF in these patients.14 On the other hand, a randomized trial on 
68 patients, who initiated cART during a primary HIV-infection showed non-inferiority of 
DTG maintenance monotherapy to cART, although the follow up period was limited. In this 
trial, one patient experienced VF, but no RAM was identified in the rebounding virus.15 The 
results of these four randomized trials clearly show that simplification to DTG maintenance 
monotherapy is not a useful clinical strategy with the current armamentarium of effective 
triple drug based cART. Currently, INSTI monotherapy is not recommended by international 
guidelines.16–18
In chapter 3, viral dynamics of patients with VF on DTG maintenance monotherapy are de-
scribed.19 Besides, DOMONO, we also conducted a DOMONO pilot study. In the latter study, 
we included patients with the same inclusion criteria as in DOMONO, except for a CD4 T-
lymphocyte nadir below 200 cells/mm3. In our DOMONO studies combined, ten patients had 
VF, including four with acquired INSTI-RAMs during DTG monotherapy compared to none 
on triple drug cART. This shows that the genetic barrier to resistance of DTG monotherapy 
is too low for maintenance of viral suppression. The large time variation to VF after start of 
DTG monotherapy (from 4 to 72 weeks) suggests that stochastic reactivation of pre-treatment 
existing proviruses, containing a single INSTI-RAM, may be the responsible mechanism 
for VF. Interestingly, we found that one patient with VF without RAMs in integrase had 
changes in the 3’polypurinetract (3’PPT). This points to a new HIV antiretroviral resistance 
mechanism in vivo, which, until now, has only been described in vitro.20 This mutation is 
thought to result in alterations of the four terminal bases of the long-terminal repeat leading 
to a decreased binding capacity of INSTIs to the integrase, while leaving its strand-transfer-
activity intact.21 This resembles a resistance mechanism also described for protease inhibitors 
(PIs).22 In four patients with VF during DTG monotherapy, the viral integrase and the 3’PPT 
were unaffected. However, it should be kept in mind that VF during INSTI-containing cART 
without the detection of RAMs in the integrasegene is observed in a substantial number of 
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patients in phase 3 studies with different INSTIs. Sequencing areas outside integrase should 
therefore be considered in these cases. Preferably this should also be done in the genome 
of non-B HIV subtypes, as the majority of data regarding mutations outside the integrase 
causing antiretroviral resistance is obtained from HIV subtype B.
We only can speculate about an ideal antiretroviral agent maintaining plasma virological 
suppression when applied as maintenance monotherapy. A number of virus- and patient-
related factors are known to be associated with plasma viral rebound. One of them is the 
viral reservoir, which could be defined as all the cells in the body that are infected with 
HIV. A theory is that in some parts of this reservoir, ongoing viral replication due to low 
antiretroviral drug levels might lead to selection of viruses with the emergence of RAMs.23–26 
A larger reservoir size might increase this chance. In chapter 4 we therefore investigated 
characteristics, including reservoir size measured as total HIV-DNA, associated with VF 
during DTG maintenance monotherapy. We found that (similar to PI monotherapy) VF was 
associated with a lower CD4 T-lymphocyte nadir, a longer time between HIV diagnosis and 
cART initiation, and a higher HIV-DNA at the time of DTG monotherapy initiation.27–31 Thus, 
the efficacy of future simplification strategies might be based on the time of infection at start 
of first line cART but this assumption needs further investigation. A low CD4 T-lymphocyte 
nadir, a longer time between HIV diagnosis and cART initiation, and a higher HIV-DNA 
at the time of DTG monotherapy initiation however seem intertwined since the longer the 
time between HIV-diagnosis and initiation of cART, the lower the CD4 T-lymphocyte nadir, 
and the higher total HIV-DNA is likely to be.32,33 Nevertheless, the results imply that the 
viral reservoir size, measured here as total HIV-DNA, plays an important role in plasma 
viral outcomes in patients on monotherapy. Future studies on simplification strategies should 
evaluate the relevance of the relation between total HIV-DNA as marker for the reservoir, 
virological suppression, and non-virological markers.34–37
Next, we investigated metabolic effects of a switch from cART to DTG maintenance 
monotherapy in chapter 5. We found that DTG monotherapy led to creatinine based esti-
mated glomerular filtration rate (eGFR) decreases but amelioration of proteinuria. No major 
clinically relevant effects on bone density, lipids, or inflammation were observed. The vast 
majority of participants in the DOMONO study was using tenofovir disoproxil fumarate 
(TDF)-containing cART, and use of TDF is associated with a number of metabolic effects: i) 
an accelerated eGFR decline, ii) renal proximal tubular dysfunction (PTD), iii) a decrease in 
bone mineral density (BMD), and iv) lowering of plasma lipids.38–43 It is therefore surprising 
that we did not observe relevant lipid changes or improvements in BMD. The eGFR decrease 
after TDF-discontinuation is unsurprising, given DTG’s inhibitory activity of renal tubular 
creatinine clearance. This leads to eGFR underestimation since this creatinine increase does 
not affect true glomerular function. True glomerular function was not measured in DOMONO, 
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but the measurements reflecting tubular function all ameliorated. The trabecular bone score 
(TBS) has not often been studied in HIV patients. It can provide additional information about 
the bone microarchitecture. Several studies suggest that a lower TBS increases the risk for 
osteoporotic fractures independently of the BMD and therefore leads to a better prediction 
of the fracture risk.44–46 Our data did not show a clinically relevant change in TBS in HIV 
patients after discontinuing TDF. It has to be studied whether TBS is a better predictor of 
the fracture risk than BMD, especially in patients at risk for osteoporosis. The stable lipid 
parameters might be a consequence of including predominantly healthy middle-aged males, 
which is also illustrated by the low Framingham Risk Score (FRS) indicating a low ten-
year cardiovascular risk in our patient cohort. Besides, stable virological suppression during 
cART-use, not necessarily TDF-containing cART, has been associated with stable low levels 
of inflammation, as well as with adequate but not normalized T-cell immunity compared to 
HIV-negative individuals. Both these factors are associated with less mortality.47,48 However, 
the results of these explorative analysis on metabolic markers still has to be interpreted with 
caution due to intrinsic limitations in our study design such as relatively few elderly, female, 
or non-Caucasion patients included, and the lack of a control-arm. Furthermore, prolonged 
simplified regimens, even in the absence of frank viremia, might still result in unfavorable 
metabolic changes due to a persistent suboptimal state of virological suppression exemplified 
by frequent viral blips for example. Although DTG monotherapy is virologically inferior to 
cART and should therefore not be considered as a useful clinical simplification strategy, the 
findings in chapter 4 and chapter 5 remain relevant for the studies on DTG-containing 
treatment strategies such as dual therapy with DTG/rilpivirine (RPV) or DTG/3TC.
To conclude, with the studies mentioned in chapters 2 to 5, unique data are available about 
the consequences of a switch to DTG monotherapy, which may have consequences for the 
use of current second-generation INSTI-containing dual therapy simplification strategies. 
In fact, several clinical trials already show favorable results of DTG/3TC, DTG/RPV, and 
cabotegravir (CAB)/RPV in virologically suppressed, but also cART-naive patients, so data 
on virological and non-virological consequences of simplification of cART using a second-
generation INSTI remain very important.49–54
Implications and future directions
Although DTG failed as maintenance monotherapy, it can still be a useful drug for simplifica-
tion strategies. Dual drug strategies including an INSTI have shown promising initial results 
and might well become the first simplification strategies that are also effective in the long 
term. This treatment strategy is the first successful switch from triple drug containing cART 
to more simplified antiretroviral strategies since the failed dual therapy strategies in the 90s 
with NRTIs. The success of dual therapy strategies with INSTI and NRTI or NNRTI might 
origin from the ongoing inhibition of the reverse transcriptase step in the HIV replication 
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cycle, as also observed for PI dual therapy.55–57 However, unfavorable immunological or 
reservoir characteristics might still interfere with maintenance of virological suppression 
by a DTG-containing dual antiretroviral regimen, illustrated by the GEMINI study where 
a subgroup analysis showed more treatment failure in patients with low CD4 T-lymphocyte 
count.49 Although VF was rare, these factors should be taken into account in future research 
on, and implementation of, INSTI-based simplification strategies. Expanding DTG dual 
therapy strategies with boosted PI would be interesting and can also provide essential infor-
mation about the necessity to inhibit the reverse transcriptase step to maintain adequate viral 
suppression rates. Furthermore, whether once daily DTG 50 mg in dual therapy strategies is 
sufficient in patients with resistance against ART classes, and the influence of dual therapies 
on reservoir evolution and inflammation, remain areas of research. It would be interesting to 
determine the most important reservoir sites for rebounding virus in individual patients and 
to improve methods to guarantee adequate intracellular antiretroviral drug-concentrations to 
stop replication. This may lead to less viral replication, less development of resistance, and 
improved virological suppression. However, these research and treatment goals seem to be 
particularly of interest for resource-rich settings. At this moment, DTG-containing dual thera-
py does not seem to be a good treatment option in the context of the 90-90-90 treatment goals 
in resource-poor countries with highly prevalent (transmitted) drug-resistance to (N)NRTI, 
less clinical and safety monitoring options, less drug-adherence, and a very high prevalence 
of Mycobacterium tuberculosis co-infections with a high risk of drug-drug-interactions and 
lower effective INSTI concentrations due to rifampicin based TB co-treatment.
With the expected inclusion of INSTI-containing dual therapy in guidelines as recommended 
HIV-treatment strategy, a unique era is approaching. After decades of studies that came to the 
conclusion that triple drug based cART should include treatment with multiple drug classes, 
resulting in varying virological efficacy, sometimes high pill burdens, drug-drug-interactions, 
and AE risks, the second generation INSTIs are the first class that can be used in clinical 
effective simplification strategies, without the risk of drug-drug-interactions that hindered 
PI simplification strategies. In the future, INSTI-containing dual therapy could very well be-
come the cornerstone of HIV induction and maintenance treatment, while new monotherapy 
strategies and cure strategies are getting developed. One of these new strategies are new ways 
to administer cART, e.g. by injection. With prolonged adequate plasma drug-concentrations 
as a result of injection of antiviral drugs the antiretroviral effect in the cells likely will be 
guaranteed. Besides, injection of antiretrovirals will cause a further reduction in pill burden. 
Another interesting future option would be if we would be able to determine, using whole 
genome sequencing, the proportions of INSTI-resistant viruses and their localization in the 
reservoir, which would help to make an a priori estimation of the virological success of 
INSTI-containing cART. With periodical repeated assessment of localization, activity, and 
sequence analyses of the whole viral population in an individual patient, instead of the current 
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practice of plasma HIV-RNA monitoring, an increasing risk on VF may be better predicted 
and emergence of RAMs may be prevented prior to the occurrence of plasma viral rebound.
safeTy of InTegRase sTRand TRansfeR InHIbIToRs
The second part of the discussion of this thesis focuses on the safety of initiation of INSTI-con-
taining cART in vulnerable patients with the acquired immunodeficiency syndrome (AIDS). 
The fast HIV-RNA decline and immunological recovery that is associated with INSTI use, 
could promote the development of an immune reconstitution inflammatory syndrome (IRIS), 
especially in those with severely immunocompromised states or opportunistic infections 
(OI).58–60 In chapter 6 we test the hypothesis that INSTI-containing cART, initiated during 
AIDS, increases the IRIS risk. In our cohort of 672 AIDS patients, we found that raltegravir 
(RAL), but not DTG or elvitegravir (EVG) initiation was associated with more IRIS develop-
ment compared to non-INSTI regimens. Furthermore, patients initiating INSTI had more 
steroid exposure, but hospitalization rates and mortality were comparable to those who initi-
ated non-INSTI regimens. Our findings are in line with another cohort study from a resource-
rich setting among 2287 hospitalized AIDS patients, although this study was hampered by a 
limited follow up period, and no distinction between INSTI were made.61 In another study of 
417 patients, a similar pattern in those exposed to INSTI was observed. Notably, the use of 
DTG and EVG, but not RAL, increased IRIS risk which is in contrast to our study and might 
partially be explained by differences in IRIS definitions.62 The findings from these cohort 
studies were, however, not reproduced in three randomized trials in which INSTI-containing 
cART was started in AIDS patients. Although IRIS risk was not the primary endpoint in these 
trials, nor were these studies designed to assess this risk, no higher incidence of IRIS after 
initiation of INSTI was reported in these studies. In the multifactorial REALITY-trial from 
sub-Sahara Africa, AIDS patients either received usual cART or intensified cART with RAL, 
next to other interventions including additional food or enhanced prophylaxis for OI. Despite 
a faster HIV-RNA decline in the RAL group, the all-cause and IRIS related mortality were not 
increased with RAL exposure.63 In the INSPIRING-study, HIV/Mycobacterium tuberculosis 
co-infected patients were simultaneously treated with rifampicin-containing antimycobacte-
rial therapy and DTG twice daily 50 mg or efavirenz (EFV) in combination with two NRTIs, 
and IRIS-rates were similar in both groups.64 Also in the OPTIMAL-trial, initiation of INSTIs 
was not associated with an increased IRIS-risk.65 Currently, the ADVANCE-trial, including 
1110 HIV patients, is ongoing in a resource limited setting where a high proportion of AIDS 
patients can be expected and in which patients are randomized to DTG based regimens or 
TDF/emtricitabine (FTC)/EFV. This study started enrollment in 2017, and week 48 data are 
expected the first quarter of 2019.66,67 Taken together, these trials do not provide evidence for 
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an increased IRIS risk with INSTI, but definite conclusions can nonetheless not be drawn due 
to the multifactorial designs and non-unified IRIS classifications.
The difference in IRIS risk between observational studies and randomized clinical trials is 
striking. It should be kept in mind however, that IRIS definitions varied between the stud-
ies and no uniform way to diagnose or study this heterogeneous disease is available.68–70 
Importantly, IRIS risk seems to differ between observational studies depending on type of 
INSTI used which hints on the difficulty of diagnosing IRIS, especially in observational 
and retrospective studies. Also, for specific OIs, additional IRIS-definitions were used by 
the investigators, which further increases the variability of IRIS definitions. Furthermore, 
confounding by indication in observational studies is likely a main confounder, which can 
divided in different considerations. Until recently, INSTI-containing cART was predomi-
nantly used in special situations. Particularly patients at a high risk of drug-drug-interactions 
initiated INSTI-containing cART, which is also the population that consists mainly of patients 
with mycobacterial infections, cancers, or other OIs.71 From 2016 on, increasing proportions 
of patients initiated DTG-containing cART, as this was recommended by guidelines. This 
means that over time, the indication for INSTI-containing cART changed, as well as the 
type of INSTI initiated. This might reduce the IRIS-risk over time, and it also increases the 
IRIS-risk of RAL relatively to DTG. However, the awareness for IRIS as a consequence of 
initiation of INSTI-containing cART may have increased, which may have led to an increase 
in IRIS-diagnoses by clinicians. On the other hand, the fear for IRIS may have increased, 
which may have resulted in avoidance of INSTIs in certain patients. These three factors might 
interact, and the net influence on the observed IRIS risk in observational studies, including 
ours, cannot be specified. Observational studies cannot fully correct for these types of biases 
in multivariable models and as such, our data should be interpreted with caution.
Until future data show otherwise, the risk of IRIS should not restrict INSTI use in AIDS pa-
tients. In the future, it can be expected that the incidence of IRIS will decline in resource-rich 
countries with the developments in healthcare leading to a decrease in HIV late presenters. 
However, in resource-poor settings, the AIDS incidence remains high, as well as the burden 
of OIs. For these settings, awareness for any potential increased IRIS risk with INSTI use 
should remain high, especially in light of the limited availability of care facilities to treat 
this complication of antiretroviral treatment. Given the fact that IRIS is not an HIV-specific 
problem (it also occurs in transplant recipients who discontinue immunosuppressive medica-
tion), knowledge about the immunological pathophysiology might be gained from these areas 
and could be extrapolated to HIV infected patients. The determination of the specific pro-
inflammatory mediators could contribute to the answer of the question whether the IRIS risk 
is increased during INSTI use, as the conclusions of cohort studies and clinical trials differ. 
Measuring IRIS-specific markers in HIV late presenters using either INSTI- or non-INSTI 
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containing cART, and relating them to clinical IRIS development, might help to distinguish 
between IRIS and other mechanisms responsible for clinical deterioration in a patient, and it 
would also help in solving the issue of heterogeneity of the IRIS syndrome.
After marketing of DTG, there is still an ongoing debate on neuropsychiatric AEs. The 
DOMONO study also provided insights regarding the association between neuropsychiatric 
AE and INSTIs, In the DOMONO study, 2% discontinued DTG for drug-related neuro-
psychiatric AEs, which is higher than observed in phase 3 registration trials. Other studies 
showed mixed signals: a meta-analysis of all phase 3 studies did not show an increased risk, 
but large cohort studies did also show an increased risk on neuropsychiatric AE. A representa-
tive prospective cohort-study including 1315 patients who discontinued INSTI-containing 
cART, showed an increased risk for patients using DTG to discontinue treatment because 
of neuropsychiatric AEs.72,73 These studies demonstrate important differences between AEs 
in trials and in real-life, and the risk on neuropsychiatric AEs can therefore not be ignored. 
Further research is warranted on the occurrence and deterioration of well-monitored neu-
ropsychiatric AEs in patients initiating INSTI-containing cART. Moreover, the underlying 
pathophysiological mechanism for INSTI-related neuropsychiatric AEs is unknown. In the 
future, it would be useful to determine neuropsychiatric substrates of INSTIs, for example 
neurotransmitter-concentrations in plasma or cerebrospinal fluid, or markers of immune 
activation which are known to be associated with neuropsychiatric symptoms. When these 
biomarkers could be determined, a screening test for the risk of neuropsychiatric AEs may 
be developed.
oPTImIzIng THe nRTI-backbone
Despite all advances in safety, use of cART is still associated with toxicity in a considerable 
number of patients. For now, the use of one or two (N)NRTIs remains the cornerstones of 
cART, as was also illustrated by the results of our DTG monotherapy study. HIV-treatment 
guidelines therefore recommend treatment with an INSTI and either an ABC- or a tenofovir 
(TDF or tenofovir alafenamide fumarate (TAF)) containing NRTI-backbone. These back-
bones are unfortunately associated with specific toxicities. TDF is used worldwide as WHO 
recommended cART. Since TDF is also generically available, recommended as pre-exposure 
prophylaxis, and active against hepatitis B, its frequent use may still result in a significant 
number of patients with, predominantly renal, toxicity.74,75 The optimal way to handle TDF-
associated renal toxicity is unknown, but the availability of TAF broadens potential NRTI 
switch options. Part 3 of this thesis centers on safety aspects of TDF-containing cART and 
possibilities to further individualize treatment of an HIV-infected individual.
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Inosine 5’-triphosphatase as predictor for Tdf-associated nephrotoxicity
A way to prevent TDF-associated nephrotoxicity is to identify patient-related risk factors. In 
chapter 7, the influence of ITPA genotype and Inosine 5’-triphosphatase (ITPase) activity on 
TDF-associated nephrotoxicity is determined. In this study, albeit the number of cases was 
limited, patients with TDF associated nephrotoxicity more frequently had a wildtype (wt)/wt 
ITPA genotype with normal ITPase activity. ITPase activity or ITPA genotype therefore might 
function as a screening- and prognostic tool for TDF-associated nephrotoxicity. In order to 
become a useful screening tool, several important issues need to be addressed. First, knowl-
edge about ITPase activity related to HIV-treatment is sparse. ITPase is an enzyme involved 
in the purine metabolism, which is responsible for the formation of DNA, and involved in 
intracellular energy-metabolism. Apart from HIV, purine analogues are also frequently used 
in the treatment of malignancies, inflammatory bowel diseases, organ transplant recipients, 
and their cellular metabolism depends partially on ITPase activity.76–78 HIV-infected indi-
viduals have a lower ITPase activity in their lymphocytes and erythrocytes, and the exact 
mechanism and effect of ITPase on the metabolism of various NRTIs is variable.76,79 Also, 
ITPase activity seems to differ between different human tissues, and it is not known whether 
erythrocyte ITPase activity, which was measured in our study, is a good surrogate of activ-
ity in renal tubular cells.80 Second, the definition of TDF-associated nephrotoxicity has to 
be more strict for successful screening. Also in our study, the interpretation of the results 
depends on the definition of TDF-associated nephrotoxicity, as we used a logical but non-
validated definition leading to potential misclassification of patients with renal dysfunction 
that were actually not caused by TDF.40 Third, the external validation of ITPase activity in 
predicting renal dysfunction and other TDF related toxicities (e.g. decreased BMD) in vari-
ous populations is essential, including an optimal cut-off. Also cost-effectiveness analyses 
should be done to assess whether testing is beneficial. The remarkable extent of recovery 
after stopping TDF in patients with normal ITPase activity cannot fully be explained by the 
removal of TDF, given a natural irreversible eGFR-decline of 1 mL/min as a result of aging 
and a long duration of TDF-use in many patients. Another explanation might be that, besides 
being involved in intracellular oxidative stress, a normal functioning ITPase also catalyzes 
the hydrolyzation of 6-N-hydroxylaminopurine (HAP), which prevents incorporation of HAP 
in the DNA, which prevents the cellular DNA from HAP’s mutagenic effects, and therefore 
catalyzes faster DNA-recovery.81 A translation of this knowledge to the relation between 
ITPA genotype, ITPase activity, and use of TAF should also be made. It is important to gain 
more insight in factors influencing ITPase-activity, and the epidemiology of ITPA genotype 
and ITPase activity. The latter provides information about the proportion of HIV-infected 
individuals who do not develop NRTI-related AEs while having a wt/wt ITPA genotype and 
normal ITPase activity. This may contribute to the usefulness of ITPase as screeningstool for 
tenofovir-toxicity. However, even in patients already using TDF-containing cART, determi-
nation of ITPase activity could contribute to more individualized care. In patients using TDF, 
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serum and urine markers of renal function should be measured at least once a year to detect 
TDF-associated nephrotoxicity as early as possible. Patients with normal ITPase activity, 
in whom TDF is considered as part of antiretroviral therapy, should be informed about the 
increased risk on TDF-associated nephrotoxicity. Patients with reduced ITPase activity, who 
use TDF, should be monitored more frequently, for example twice a year, and when the first 
signals of nephrotoxicity occur, TDF should immediately be discontinued, as recovery of 
TDF-associated nephrotoxicity is less likely in those patients. In conclusion, ITPase activity 
might be useful in cases of TDF treatment or where TDF initiation is considered, but its exact 
place should be elucidated.
Recovery of Tdf-associated nephrotoxicity
HIV-treatment guidelines advise to discontinue TDF in case of renal tubulopathy or evidence 
of decreased glomerular function, and to initiate ABC- or TAF-containing cART-regimens 
instead.17,18 ABC and TAF in NRTI backbones of cART have comparable virological efficacy. 
However, direct comparative renal recovery analyses of ABC versus TAF in patients with 
TDF-associated nephrotoxicity are unavailable.82 In chapter 8, this knowledge gap has been 
studied and renal recovery rates after discontinuing TDF for renal toxicity are reported. This 
interim analysis showed that regardless of switching to ABC or TAF containing cART, the 
eGFR decline stabilizes. Furthermore, proteinuria decreased, virological suppression rates 
remained high, and the beneficial lipid effect of TDF waned similarly in both groups. Longer 
follow up should further strengthen these results.83–88 These findings, especially in combina-
tion with ITPase findings, can contribute to further individualization of HIV-treatment.
future perspectives on tenofovir-containing antiretroviral therapy
In the future, patients will likely be more in the lead of their own healthcare process, which 
could be an improvement for their dedication to their own health. Providing patients with 
exact knowledge about the advantages and risks of TDF, and other ART, and gaining more 
knowledge on factors involved in toxicity could help them and their health care profession-
als to make the best choices for their HIV-treatment. Patients at the lowest risk of VF and 
AE could be identified, and this knowledge could be valuable to tailor cART regimens for 
individual patients.
concludIng RemaRks
The effectiveness and safety of new HIV treatment strategies including INSTIs and NRTI 
backbones in HIV infected individuals will likely remain important in the upcoming decades 
since the prospect of a cure is still unclear. This thesis helps to individualize patient care by 
showing what and how several first-line drugs, which will remain important in the upcoming 
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decade due to worldwide roll-out should be used, and which strategies should be avoided. The 
main conclusions are that:
i) DTG should not be used as maintenance monotherapy for viral efficacy, since INSTI-
resistance acquired on DTG monotherapy is frequent and may be caused by mutations 
outside the integrase gene. The viral reservoir size and activity are likely to be useful as 
predictor for VF during simplification strategies.
ii) INSTI containing cART is safe in AIDS patients and not associated with an increased 
IRIS-related mortality risk.
iii) ITPA genotype and ITPase activity may be future biomarkers for toxicity during TDF use, 
and ABC or TAF can both be used for optimal renal recovery in cases of TDF-related 
nephrotoxicity.
Future research should remain focused on safe and efficacious HIV-treatment strategies 
especially with newer simplification regimens, development and effect of existing and new 
antiretroviral resistance mechanisms, and improve ways to predict virological success and 
toxicity on ART. These research goals contribute to more individualized care, which will 
further optimize HIV-treatment, until curing HIV is possible.
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Het humaan immuundeficiëntie virus type 1 (HIV) infecteert afweercellen, voornamelijk 
CD4 T-cellen, in het menselijk lichaam. Zonder behandeling leidt dit tot een steeds ergere 
aantasting van de afweer. Het gevolg hiervan is dat mensen het acquired immune deficiency 
syndrome (beter bekend als AIDS) ontwikkelen. AIDS is het eindstadium van een HIV-
infectie waarbij mensen zo weinig afweercellen hebben, dat ze ernstige infecties krijgen. Dit 
zijn specifieke infecties die alleen mensen met een slechte afweer kunnen krijgen, en mensen 
met een gezond afweersysteem niet. Uiteindelijk overlijden mensen aan deze infecties. Le-
venslang dagelijkse behandeling met medicijnen tegen HIV, ofwel antiretrovirale therapie, 
zorgt ervoor dat het virus onderdrukt wordt. Dit leidt tot herstel van de afweer, waardoor 
AIDS en overlijden aan de bijbehorende specifieke infecties voorkomen worden. De levens-
verwachting van een HIV-geïnfecteerd persoon is dan nagenoeg hetzelfde als die van een 
ongeïnfecteerd persoon. Verder is de kans op overdracht van HIV via seksueel contact en van 
moeder op kind heel erg klein bij mensen met een virus dat in het bloed door antiretrovirale 
therapie onderdrukt is. Hierdoor zijn mensen die het virus niet hebben, beschermd tegen het 
krijgen van een HIV-infectie. Naast virologische onderdrukking leidt antiretrovirale therapie 
ook tot vermindering van een ontstekingsreactie in het lichaam, veroorzaakt door HIV. Dit 
soort reacties kunnen onder andere vaatschade geven, en daarmee leiden tot bijvoorbeeld 
hart- en vaatziekten. Ook verkleint behandeling van HIV het risico op diverse kankersoorten.
HIV is een retrovirus. Dat wil zeggen dat het virus het eiwit reverse transcriptase bevat. 
Reverse transcriptase kan het genetisch materiaal van het virus, het ribonucleïnezuur (RNA), 
omzetten in desoxyribonucleïnezuur (DNA). Het eiwit integrase kan vervolgens viraal DNA 
in het humaan DNA in cellen inbouwen. HIV misbruikt vervolgens deze cel om nieuwe 
virusdeeltjes te maken, die in het bloed terechtkomen. Deze nieuwe virusdeeltjes kunnen 
vervolgens weer nieuwe cellen besmetten. Op deze manier vermenigvuldigt HIV zich in 
het lichaam. Dit staat bekend als de replicatiecyclus van HIV. Verschillende stappen in deze 
replicatiecyclus kunnen we tegenwoordig remmen met antiretrovirale therapie.
Vijf vrijwel overlappende HIV-behandelrichtlijnen zijn wereldwijd het belangrijkst. De ge-
meenschappelijke aanbeveling van de richtlijnen is om alle mensen met HIV zo snel mogelijk 
te behandelen met een combinatie van drie antiretrovirale medicijnen. Dit wordt ook wel triple 
antiretrovirale therapie genoemd. De reden hiervoor is dat de genetische informatie van HIV 
snel kan veranderen doordat er mutaties optreden. Door mutaties wordt het virus ongevoelig 
(ook wel resistent genoemd) voor één of meerdere medicijnen tegen HIV. Hierdoor kan het 
virus weer ongeremd in het lichaam gaan vermenigvuldigen. Door HIV met een combinatie 
van verschillende antiretrovirale medicijnen te behandelen, is de kans op resistentie erg klein. 
Daardoor is de kans dat het virus in het bloed onderdrukt blijft, groot. De huidige triple 
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antiretrovirale therapie remt op twee verschillende manieren de replicatiecyclus. Momenteel 
wordt geadviseerd om twee remmers van het eiwit reverse transcriptase te combineren met 
een derde HIV-remmer die een ander onderdeel van de replicatiecyclus remt. Deze derde 
HIV-remmer kan een ook een reverse transcriptase remmer met een ander aangrijpingspunt 
zijn, een remmer van het virale eiwit protease, dat het virus nodig heeft om tot een functioneel 
virusdeeltje te worden na het vrijkomen uit de cel, of een remmer van het virale eiwit integrase. 
Voor Westerse landen adviseren de richtlijnen nu een behandeling met een integraseremmer 
in combinatie met twee reverse transcriptase remmers. Omdat integraseremmers nieuw zijn, 
en weinig beschikbaar in armere landen, wordt in deze landen nog veelal een combinatie 
van twee reverse transcriptase remmers en een reverse transcriptase remmer met een ander 
aangrijpingspunt gebruikt.
Bij het starten van triple antiretrovirale therapie komt meer kijken dan alleen een zo goed 
mogelijke onderdrukking van het virus. Er dient ook rekening gehouden te worden met de 
beschikbaarheid van medicijnen in bepaalde delen van de wereld, de kosten van de medicatie, 
de bijwerkingen en het innamegemak. Een integraseremmer geeft hele goede onderdrukking 
van het virus, vaak beter dan andere HIV-remmers. Daarom gebruikt men bij voorkeur triple 
antiretrovirale therapie die een integraseremmer bevat. Daarnaast geeft triple antiretrovirale 
therapie met een integraseremmer weinig bijwerkingen en is het makkelijk in te nemen.
Hoewel de behandeling van HIV volgens de behandelrichtlijnen met triple antiretrovirale 
therapie leidt tot goede onderdrukking van het virus, is het onbekend of drie medicijnen voor 
alle HIV-geinfecteerde mensen noodzakelijk zijn. Daarnaast zijn de risico’s van het gebruik 
van integraseremmers bij mensen met AIDS of andere aandoeningen naast hun HIV-infectie 
nog niet zo goed bekend. De vraag is dus in hoeverre triple antiretrovirale therapie op deze 
patiëntencategorieën van toepassing is, en of er mogelijkheid of noodzaak is om bij indivi-
duele patiënten daarvan van af te wijken. Hierdoor zou hun behandeling nog beter, veiliger 
en minder belastend kunnen worden. Het doel van dit proefschrift is om met nieuwe kennis 
bij te dragen aan een optimale en veilige onderdrukking van HIV met nieuwe en bestaande 
antiretrovirale behandelingen, waarbij integraseremmers centraal staan.
Men probeert al heel lang om HIV met minder dan drie antiretrovirale medicijnen te behande-
len. Dit heet versimpeling van therapie. Succesvolle versimpeling kan vele voordelen hebben, 
waaronder minder bijwerkingen, minder kosten en meer gebruiksgemak. Dit lukte niet met 
alleen reverse transcriptase remmers of protease remmers, doordat het virus in het bloed on-
voldoende onderdrukt bleef. Daarnaast werd het virus te vaak resistent tegen deze middelen, 
en kwam het terug in het bloed. Als het virus terugkomt in het bloed doordat antiretrovirale 
therapie niet werkt, bijvoorbeeld door resistentie, wordt gesproken van virologisch falen.
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Sinds een aantal jaar zijn de integraseremmers beschikbaar voor de behandeling van HIV. Er 
zijn twee groepen integraseremmers: de eerste en de tweede generatie. De tweede generatie 
integraseremmers zijn zeer krachtig in het onderdrukken van het virus, en resistentie tegen 
deze klasse ontstaat nauwelijks. Eén van de tweede generatie integraseremmers is dolutegra-
vir. Tot nu toe lijkt de ontwikkeling van resistentie tegen dolutegravir nauwelijks mogelijk 
bij HIV-patiënten die dolutegravir als eerste integraseremmer gebruiken, dus zonder dat er 
eerder een eerste generatie integraseremmer gebruikt is. De gunstige eigenschappen van do-
lutegravir zouden het mogelijk kunnen maken om HIV-behandeling met triple antiretrovirale 
therapie te versimpelen tot alleen dolutegravir, dus zonder andere antiretrovirale medicijnen 
erbij. Dit noemen we monotherapie. In deel 1 van dit proefschrift onderzoeken we daarom 
of alleen dolutegravir voldoende is om het virus te onderdrukken. Behandeling met deze 
therapie vergelijken we met de gebruikelijke behandeling met triple antiretrovirale therapie.
In hoofdstuk 2 vergelijken we in het DOlutegravir MONOtherapie voor HIV-1 onderzoek 
(DOMONO) de effectiviteit en veiligheid van dolutegravir monotherapie met die van triple 
antiretrovirale therapie bij 95 HIV-patiënten met een onderdrukt virus door triple antiretro-
virale therapie. De helft van deze mensen stopte de triple antiretrovirale therapie en kreeg 
dolutegravir monotherapie, en de andere helft continueerde de triple antiretrovirale therapie. 
Gedurende het eerste half jaar was de mate van onderdrukking van het virus vergelijkbaar 
in beide groepen, maar daarna ontwikkelden maar liefst acht patiënten met dolutegravir 
monotherapie virologisch falen ten opzichte van nul patiënten met virologisch falen die triple 
antiretrovirale therapie gebruikten. Drie van deze acht mensen hadden een gemuteerd virus. 
Vanwege deze ontwikkeling hebben we de studie gestaakt. Wij vinden dat bij mensen met 
HIV, bij wie het virus onderdrukt is met triple antiretrovirale therapie, versimpeling door 
dolutegravir monotherapie niet geschikt is.
In hoofdstuk 3 gaan we dieper in op deze gemuteerde virussen. In een verwant onderzoek 
hadden nog twee mensen virologisch falen tijdens dolutegravir monotherapie. Hun virussen, 
samen met de virussen van de mensen met virologisch falen uit het DOMONO-onderzoek, 
hebben we onderzocht. In totaal hebben we tien virussen onderzocht. Bij resistentie onderzoek 
bekijken we normaal gesproken een klein stukje virus dat codeert voor het integrase eiwit 
(het integrase gen). Hierin zoeken we naar mutaties. Het virus is echter groter en mutaties 
buiten dit stukje kunnen mogelijk ook van invloed zijn op de gevoeligheid van het virus voor 
dolutegravir. Daarom hebben we nu ook gekeken naar het virus buiten het integrase gen. 
Bij vier van de patiënten met virologisch falen ontwikkelde het virus tijdens monotherapie 
mutaties in het integrase gen die zorgen voor resistentie tegen integraseremmers. Uniek was 
dat bij één andere patiënt de mutaties op een zeldzame plek buiten het integrase gen werden 
gevonden. Dit is een nieuw resistentiemechanisme, dat nog nooit bij een virus in een HIV-
patiënt aangetoond was. Dit impliceert dat bij virologisch falen de mutaties, die zorgen voor 
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resistentie tegen de behandeling, ook in andere delen van het virus kunnen optreden. De 
oorzaak van het virologisch falen met monotherapie berust mogelijk op het feit dat HIV nooit 
helemaal weg is uit het lichaam, ondanks antiretrovirale therapie. Het verstopt zich namelijk 
in zogenaamde reservoirs waar het gedurende jaren aanwezig kan zijn in vrijwel inactieve 
staat. In het reservoir kunnen ook virusdeeltjes zitten die al een mutatie bevatten. Wanneer 
zo’n virusdeeltje uit het reservoir actief wordt, lijkt monotherapie onvoldoende om de verme-
nigvuldiging te stoppen. Het is nu nog niet te voorspellen of en wanneer dit gebeurt, waardoor 
het onzeker is of de huidige en toekomstige behandelstrategieën met monotherapie tot goede 
virologische onderdrukking zonder ontwikkeling van resistentie kunnen gaan leiden.
In hoofdstuk 4 zoeken we naar voorspellers van het virologisch falen in het DOMONO-
onderzoek. Een belangrijke factor die we vonden, was de totale hoeveelheid genetisch 
materiaal van het virus in het lichaam: het HIV-DNA. Het HIV-DNA vormt een maat voor de 
grootte van het HIV-reservoir. Het HIV-reservoir is van belang, omdat een groter of actiever 
reservoir de kans op virologisch falen hoogstwaarschijnlijk vergroot. Virologisch falen in het 
DOMONO-onderzoek bleek gerelateerd aan een groter reservoir, een slechtere afweer, en 
een langere periode zonder behandeling met medicijnen na het stellen van de HIV-diagnose. 
Deze factoren houden verband met elkaar: des te langer er gewacht wordt met behandeling 
van HIV, des te groter het HIV-reservoir wordt, en des te meer de afweer wordt aangetast. 
Deze bevindingen onderschrijven dat de grootte van het reservoir en de staat van de afweer 
belangrijke voorspellers zijn van virologisch falen op monotherapie.
In hoofdstuk 5 beschrijven we de effecten van een versimpeling van triple antiretrovirale 
therapie naar dolutegravir monotherapie op de metabole processen in het lichaam. Bijna alle 
deelnemers aan het DOMONO-onderzoek gebruikten voor hun versimpeling naar dolutegra-
vir monotherapie het middel tenofovir disoproxil fumaraat (TDF) in hun triple antiretrovirale 
medicatie. TDF kan schadelijk zijn voor de nieren en voor de botsterkte. Aan de andere kant is 
een gunstig metabool effect van TDF dat het zorgt voor een lager cholesterol. Aangezien veel 
patiënten TDF staakten, verwachtten we dat de nieren en botsterkte zouden verbeteren, maar 
ook dat het cholesterol zou stijgen. Bij de deelnemers aan het DOMONO-onderzoek vonden 
we een verbetering van de nierfunctie, maar de waarden van de botsterkte, het cholesterol, 
de afweer en ontsteking in het lichaam bleven stabiel. De relatief gezonde studiepopulatie en 
de onderzoeksduur van slechts één jaar hebben mogelijk bijgedragen aan deze bevindingen.
Het gebruik van integraseremmer bevattende triple antiretrovirale therapie geeft een snelle 
daling van de hoeveelheid virusdeeltjes in het lichaam, en het leidt tot snel herstel van de 
afweer, sneller dan andere klassen medicatie. Deze effecten zijn helaas risicofactoren voor 
het optreden van een heftige afweerreactie. Deze afweerreactie staat bekend als het immuun 
reconstitutie inflammatoir syndroom (IRIS). IRIS kan optreden bij mensen die AIDS hebben 
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en bij wie de afweer plotseling snel herstelt. Van IRIS kunnen mensen erg ziek worden en 
zelfs overlijden. Vaak zijn ziekenhuisopnames of extra medicijnen noodzakelijk. De veilig-
heid van integraseremmer bevattende triple antiretrovirale therapie bij AIDS-patiënten wordt 
onderzocht in deel 2 van dit proefschrift.
In hoofdstuk 6 wordt de relatie onderzocht tussen het starten van integraseremmer bevattende 
triple antiretrovirale therapie bij mensen met AIDS en het optreden van IRIS. In een groep 
van 672 AIDS-patiënten die startten met triple antiretrovirale therapie, hebben we onderzocht 
of zij IRIS ontwikkelden. Mensen die een integraseremmer startten, hadden inderdaad een 
verhoogd IRIS-risico ten opzichte van mensen die geen integraseremmer startten. Opval-
lend was dat dit vooral patiënten betrof die de eerste generatie integraseremmer raltegravir 
gebruikten, terwijl we dit bij dolutegravir en de eerste generatie integraseremmer elvitegravir 
niet vonden. We vermoeden dat dit resultaat wordt verklaard door andere verschillen tussen 
patiënten die deze medicatie gebruikten.
Voor 2016, toen integraseremmer bevattende triple antiretrovirale therapie nog niet door de 
behandelrichtlijnen aanbevolen werd, en dolutegravir nog maar net op de markt was, werd 
raltegravir alleen voorgeschreven aan HIV-patiënten die erg ziek waren. Deze patiënten had-
den bijvoorbeeld lymfeklierkanker, tuberculose of hersenvliesontsteking door cryptococcen 
(cryptococcen meningitis) bij hun HIV. Bij deze aandoeningen moeten veel andere medicij-
nen voorgeschreven worden. Het is dan van belang om het risico op medicatie-interacties 
zo laag mogelijk te houden, en dat gaat het beste met een integraseremmer. In die tijd was 
dit doorgaans raltegravir. Mensen die het hoogste risico liepen op een IRIS kregen daarom 
ook het vaakst de integraseremmer raltegravir, en minder vaak een behandeling met een 
antiretroviraal medicijn uit een andere klasse. Hierdoor is een vertroebeling van de resultaten 
opgetreden. Daarnaast wordt de ontwikkeling van IRIS bij mensen die raltegravir kregen 
vermoedelijk verder versterkt door onbekende factoren. Of de eigenschappen van integrase-
remmers leiden tot meer of andere immuunreacties in vergelijking met andere HIV-remmers 
is nog onduidelijk. Vooralsnog lijken de nadelen niet op te wegen tegen de voordelen van 
integraseremmers bij AIDS-patiënten.
Triple antiretrovirale therapie moet in een substantieel aantal patiënten vroeg of laat wel 
eens onderbroken worden vanwege bijwerkingen. Integraseremmers worden altijd samen met 
reverse transcriptase remmers gebruikt. De reverse transcriptase remmers worden daarom 
veel gebruikt en kunnen ook bijwerkingen veroorzaken. In de klasse van reverse transcriptase 
remmers zijn drie belangrijke medicijnen beschikbaar: abacavir, TDF en tenofovir alafena-
mide fumaraat (TAF). Deze middelen zijn allemaal in gelijke mate effectief, maar verschillen 
qua bijwerkingen. Het gebruik van abacavir kan leiden tot een ernstige allergische reactie, 
en is geassocieerd met hart- en vaatziekten bij bepaalde risicogroepen. Nierschade is een 
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belangrijke bijwerking van langdurig TDF-gebruik. TAF en TDF lijken erg op elkaar, allebei 
de middelen bevatten namelijk tenofovir. TAF en TDF zijn in gelijke mate effectief tegen 
het virus. Een belangrijke bijwerking van langdurig gebruik van middelen met tenofovir is 
nierschade. Omdat de dosering van TAF veel lager is dan die van TDF, hoeft minder TAF 
gebruikt te worden en treden de bijwerkingen van tenofovir minder op. TDF wordt niet alleen 
als behandeling van HIV gebruikt. Het voorkomt ook overdracht van HIV bij mannen die 
seks hebben met mannen, en kan gebruikt worden bij hepatitis B-infecties. De komende jaren 
zal TDF in grote delen van de wereld een veelgebruikt middel blijven, ondanks dat er soms 
betere alternatieven beschikbaar zijn. Om deze reden zullen de bijwerkingen van TDF een 
belangrijk probleem blijven. In het derde deel van dit proefschrift onderzoeken we of we de 
nierschade van TDF beperkt kunnen houden.
Hoofdstuk 7 beschrijft onderzoek naar een bloedbepaling die mogelijk uit zou kunnen wijzen 
of mensen een verhoogd risico hebben om tijdens TDF-gebruik nierschade te ontwikkelen. 
Het inosine 5’-trifosfatase (ITPase) is een enzym dat onder andere betrokken is bij de afbraak 
van TDF in de cel. De meeste mensen hebben een normaal werkend ITPase, maar sommigen 
hebben een verminderde werking van het ITPase. Het stukje genetische informatie dat codeert 
voor ITPase heet het ITPA gen. Het is niet duidelijk in welke mate mutaties in het ITPA gen 
en de ITPase activiteit gerelateerd zijn aan schadelijkheid van TDF. HIV-geïnfecteerden met 
een normale ITPase-activiteit vertonen een iets grotere achteruitgang in nierfunctie tijdens 
TDF gebruik, maar ook een meer uitgesproken herstel na het staken ervan, ten opzichte van 
mensen met een verminderde ITPase activiteit. Er werd geen duidelijk verband gevonden tus-
sen mutaties in het ITPA gen en het optreden en herstellen van nierschade door TDF-gebruik. 
Alhoewel het precieze werkingsmechanisme onbekend is, en er meer onderzoek moet volgen, 
zou ITPase mogelijk in de toekomst gebruikt kunnen worden om te voorspellen bij welke 
patiënten nierschade door TDF optreedt.
In hoofdstuk 8 onderzoeken we of het vervangen van TDF door TAF- of abacavir-bevattende 
triple antiretrovirale therapie bij mensen met nierschade door TDF goede en vergelijkbare 
alternatieve behandelopties zijn. Bij mensen die naar TAF- of naar abacavir-bevattende tri-
ple antiretrovirale therapie switchen, stabiliseerde de nierfunctie in gelijke mate. TAF- en 
abacavir-bevattende triple antiretrovirale therapie lijken beide dus goede alternatieven voor 
TDF-bevattende triple antiretrovirale therapie, wanneer nierschade door TDF is opgetreden.
De inzichten die in dit proefschrift verworven zijn, worden samengevat en bediscussieerd in 
hoofdstuk 9. De belangrijkste conclusies van dit proefschrift zijn:
i) dolutegravir is niet geschikt om als monotherapie het virus in het bloed onderdrukt te 
houden. Resistentie van het virus tegen integraseremmers treedt veelvuldig op bij mo-
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notherapie en kan veroorzaakt worden door mutaties buiten het integrase gen. Het HIV-
reservoir, evenals de staat van de afweer zijn bruikbaar als voorspeller van effectiviteit 
van HIV-behandeling tijdens versimpelingsstrategieën.
ii) integraseremmer bevattende triple antiretrovirale therapie is veilig bij AIDS-patiënten 
zonder een duidelijke associatie met het ontwikkelen van IRIS.
iii) ITPase enzym activiteit kan helpen bij het voorspellen en voorkomen van nierschade 
door TDF. Als er nierschade optreedt, dan zijn abacavir en TAF bevattende triple antire-
trovirale therapie gelijkwaardig om te gebruiken om de toename van nierfunctieverlies te 
voorkomen.
Het doel van dit proefschrift is om met nieuwe kennis bij te dragen aan een optimale en 
veilige onderdrukking van HIV met nieuwe en bestaande antiretrovirale behandelingen met 
een focus op integraseremmers. Deze conclusies helpen om een betere HIV-behandeling op 
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Daar zijn ze dan, die o zo belangrijke laatste pagina’s van dit proefschrift. Op een positie in 
het proefschrift waar ze makkelijk en snel te vinden zijn, zodat de inhoud ervan niet aan de 
verdiende aandacht ontsnapt. Tijdens mijn promotieonderzoek en de totstandkoming van dit 
proefschrift kende ik dalen en pieken waar ik nooit eerder mee geconfronteerd was. Degenen 
zonder wie dit proefschrift nooit het succes geworden zou zijn wat het nu is, en degenen die 
me in voor- en tegenspoed bijstonden, wil ik graag bedanken.
Allereerst gaat mijn zeer grote dank uit naar de patiënten die deelnamen aan de studies en hun 
gegevens beschikbaar stelden voor onderzoek. Zonder uw deelname aan onderzoek, waarbij 
u zo graag iets voor andere HIV-patiënten wilde betekenen, zouden we als wetenschappers 
niet de stappen kunnen maken die we nu maken. U motiveerde en inspireerde me telkens 
weer.
Mijn co-promotor dr. Bart Rijnders, beste Bart, wat ben ik ontzettend trots en wat voel ik 
me nog altijd vereerd dat ik promotieonderzoek heb mogen doen onder jouw supervisie. De 
keren dat ik blij verrast werd door je vindingrijkheid en je creativiteit zijn ontelbaar, en ik 
heb ontzettend veel geleerd van de steengoede internist-infectioloog en wetenschapper die je 
bent. Bedankt voor deze fantastische ervaring en het vertrouwen dat ik altijd van je gekregen 
heb. Ik had nooit kunnen vermoeden dat onze eerste kennismaking in de Bazar in Rotterdam 
tot zo veel goeds zou leiden.
Mijn co-promotor dr. Casper Rokx, lieve Casper, CrisprCas, ik weet niet waar ik moet begin-
nen. Je bent het niet erg van me gewend, maar in dit geval heb ik toch moeite om mijn dank 
aan jou te verwoorden. Van je hulp bij het opzetten van studies tot het kritisch becommen-
tariëren van stukken, zonder jou was dit proefschrift er nooit gekomen. Niet onbelangrijk is 
ook mijn introductie door jou in de Rotterdamse borrelscene, een essentieel stukje opvoeding 
voor iedere promovendus, in ons geval een succesformule met een lach en een traan. Alle 
goeds gewenst samen met Lotte en jullie kindjes, en ik ben trots op de internist-infectioloog 
en wetenschapper die je ook bent! Toedeledokie, IngeMountain.
Mijn promotor Prof. dr. Annelies Verbon, beste Annelies, ik bewonder je niet alleen als 
wetenschapper, maar ook als clinicus en organisator. Naast je immer verhelderende visie op 
wetenschap, waarbij door jouw scherpe blik stukken altijd veel beter werden, zag jij met jouw 
creativiteit altijd mogelijkheden voor nieuwe inspirerende projecten en stukken. Daarnaast 
ben je ook op organisatorisch en klinisch gebied een groot voorbeeld voor me. Heel veel dank 
voor alle kansen die ik van je gekregen heb en alles wat ik van je heb mogen leren.
238 Chapter 11
Ik wil graag de leescommissie hartelijk danken voor de snelle beoordeling van mijn proef-
schrift en hun zittingname in mijn commissie.
Prof. dr. Eric van Gorp, beste Eric, het is een grote eer voor mij dat jij met jouw wetenschap-
pelijke en virologische achtergrond deel uit wil maken mijn commissie.
Prof. dr. Peter Reiss, beste Peter, ik ben heel blij met het prachtige onderzoek wat ik in 
samenwerking met de SHM heb mogen doen. Met jouw klinische ervaring ben je een groot 
inspirator voor mij. Veel dank voor de zittingname in mijn commissie en alles wat ik van je 
heb mogen leren.
Prof. dr. Linos Vandekerckhove, beste Linos, naast de Gentse-Rotterdamse samenwerking 
met een zeer mooi eindresultaat, ben ik je ook dankbaar dat je in mijn leescommissie plaats 
hebt willen nemen.
Prof. dr. Eric van Wijngaerden, Prof. dr. André van der Ven en dr. Stephanie Klein Nagelvoort-
Schuit, veel dank voor uw zittingname in mijn grote commissie. Het is mij een grote eer met 
u van gedachten te mogen wisselen over dit proefschrift.
Dank aan alle internist-infectiologen, Prof. dr. A. Verbon, dr. B.J.A. Rijnders, dr. C.A.M. 
Schurink, dr. T.E.M.S. de Vries-Sluijs, dr. H.I. Bax, dr. J.L. Nouwen, Prof. dr. E.C.M. van 
Gorp, dr. M.E. van der Ende en N.C. Peltenburg, beste Annelies, Bart, Karin, Dorine, Han-
nelore, Jan, Eric, Ineke en Chantal, dank voor jullie bijdrage aan de studies en de manuscrip-
ten. Ook wil ik jullie hartelijk danken voor de leerzame jaren waarin ik als internist in spé 
zoveel heb mogen leren over HIV en infectieziekten in bredere zin. Mijn grote dank gaat ook 
uit naar Jan, Nadine, Laura en Marion, die me met enige regelmaat op de poli infectieziekten 
hielpen met de zorg, mijn kennis bijspijkerden en met wie ik ook gewoon eens een fijn bab-
beltje kon maken. René, dank je voor alle hulp bij de studies en ál het prikken! Kader, geen 
mailtje was jou en je collega’s teveel, zonder jou was de agenda een zooi geworden. Sandra, 
zelfs voor die ene DEXA-scan had je altijd een gaatje, ook als er zelfs geen gaatje meer was 
eigenlijk! Ik waardeer je inspanningen enorm!
Ik wil graag alle co-auteurs danken voor de prettige samenwerking en de mooie resultaten die 
we samen behaald hebben. Ferdinand Wit, beste Ferdinand, jouw (statistische) ondersteuning 
heeft geleid tot zeer interessante inzichten in IRIS-casuïstiek in Nederland. Dank voor alle 
brainstorm-sessies en je geduldige uitleg. Wouter Bierman, beste Wouter, de vele ritjes naar 
Groningen waren het meer dan waard, wat hebben we mooi onderzoek gedaan. Chantal 
Peltenburg, lieve Chantal, wauw! Het liep en het was top! Enorm bedankt voor onze samen-
werking op het gebied van ITPase, al je support in de soms zware tijd en de gezelligheid in 
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Boston. Charles Boucher, beste Charles, je enthousiasme en je geniale blik op de virologie 
enthousiasmeerden me keer op keer. Ook dank voor alle inzichten in de virologie die je me 
verschaft hebt. Jeroen van Kampen, beste Jeroen, nadat ik in het begin een enkele keer per 
ongeluk op vrijdagmiddag laat nog PBMC’s liet komen, startte het eigenlijk pas echt, de 
succesvolle samenwerking tussen virologie en kliniek voor de DOMONO-studie. Veel dank 
voor de fijne samenwerking, de brainstormsessies en de successen die we geboekt hebben! 
Leonie de Groot en collega’s van de SHM, door jullie is het IRIS-onderzoek een gigantisch 
succes geworden, dank daarvoor.
Onderzoekscollega’s, samen komen we er wel, als één van ons even de moed dreigde te 
verliezen, was er altijd wel iemand die er op het promotie-ganzenbord van de Z-flat nog 
beroerder voor stond. Dank voor alle gezelligheid, inspirerende koffie- en borrelmomenten 
en jullie luisterend oor. Bas, zonder jouw basic life support voor promovendi, werken met 
Graphpad bijvoorbeeld, of iedere dag lunchen, was ik de eerste maand niet eens doorgekomen. 
Anne, samen van het begin als jonge eendjes tot doorgewinterde onderzoeksters, dit hebben 
we maar mooi gedaan! Nu samen, weliswaar allebei aan een andere kant van Rotterdam, op 
naar de volgende mijlpaal. Ga-Lai, wat moest ik zonder je luisterend oor, je praktische tips 
(nadat een poster gedrukt is, pas op congres weer uit de koker halen) en jouw onverwachte 
hilarische acties? Alexander, met jouw haarscherpe bewoordingen en grappen krijg je altijd 
een grote grijns op mijn gezicht. Ik ben trots op je en wij kaaskoppen mogen blij zijn met jou 
als Vlaamse internist-hematoloog in onze gelederen. Stephanie, aan een half woord genoeg, 
en altijd een luisterend oor, wat is me dat veel waard. Thanks dat ik ook op ander terrein de 
kunst bij je af mocht kijken! Henrieke, het was weliswaar niet zo lang, maar ik koester ons 
gezamenlijk arts-onderzoekerschap bij de infectieziekten. Die borrel gaat er komen, kan best 
na de 5 km in 18.45! Albert, aan vrolijkheid geen gebrek! Het waren mooie maanden en ik 
hoop nog vaak om je te mogen lachen. Rosanne, je gaat een prachtig proefschrift maken, en 
de BACTAF wordt één van jouw successen. Ik waardeer onze gezellige en goede samenwer-
king, ook in Ari. Cynthia, I enjoyed our stay in Milan, it was very nice to refer everyone to 
you after my short clinical introduction on the 3’PPT. Sofie, alsof we al jaren collega’s waren, 
zaten we aan de koffie op Breda Centraal. Dank je voor de mooie samenwerking.
Arts-assistenten Interne geneeskunde van het Amphia ziekenhuis, dank jullie voor het warme 
welkom, die borrels staan op mijn prioriteitenlijst, écht! Lieve oud-Amphia-collega’s, het 
waren hele mooie tijden waar ik jullie heel dankbaar voor ben! De koffie-momentjes in het 
Erasmus MC met jullie hielden me op de been. Beste internisten en MDL-artsen van het 
Amphia ziekenhuis, veel dank voor al jullie geduld en alle leermomenten. Joost, jouw speech 
aan mijn adres over Winston Churchill was één van de kleine zetjes in de goede richting. 
Hopelijk volgen er nog vele. Coen, ik kreeg als piepjong doktertje van jou de kans, oneindig 
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veel dank daarvoor. Gerba, toen het echt nodig was, bood je een luisterend oor en zei je het 
juiste, dank daarvoor.
AIOS Infectieziekten en Medische microbiologie van het Erasmus MC, op een koude maan-
dagochtend in december 2015 stond ik opeens met mijn boodschappentassen vol ordners op 
Na09. Ik vond een plekje en ik mocht altijd deel uitmaken van de gezellige werksfeer, alle 
sociale activiteiten en de koffierondjes. Daarnaast kon ik altijd wel iemand om promotie-
gerelateerd advies vragen. Veel dank dat ik deel uit mocht maken van de groep. Ook heel veel 
dank voor jullie oneindige geduld ten aanzien van mijn matige lunchgewoonten, het blijft een 
zwakke plek, maar ik doe mijn best!
Studenten geneeskunde Maarten, Anneloes, Ghariba, Vera, Maartje en Joyce, veel dank voor 
de samenwerking, jullie inspanningen voor de onderzoeken en alles wat ik van jullie mocht 
leren. Jullie zijn of worden top-dokters! Joyce, ik verliet met een meer dan gerust hart het 
ziekenhuis voor een paar maandjes, dank voor je eeuwige geduld als ik weer eens (niet) belde, 
mailde, appte, te laat kwam of iets vergat!
Mirjam (Mirrieeeee) en Gert-Jan, Michelle en Michiel, Amanda en Arnoud, als er in mijn 
agenda al tijd was om iets met jullie af te spreken, was ik vaak moe, klaagde ik over drukte, of 
vertelde ik verhalen over mijn promotie die waarschijnlijk niet te volgen waren. Jullie gezel-
schap, samen met jullie lieve kindjes, is me heel veel waard, evenals jullie goede zorgen voor 
en betrokkenheid bij Sander en Tobias. Het hield mijn ogen open voor wat echt belangrijk 
voor me is in het leven. Vanaf nu heb ik weer veel meer tijd en energie voor etentjes bij de 
Hoofdwacht, kopjes thee en koffie in het zonnetje en dates bij Monkeytown!
Merel, lieve Merel, weet je nog hoe het allemaal begon, zo’n 10 jaar geleden? Wat hebben 
we door de jaren heen veel meegemaakt en een fijn luisterend oor aan elkaar gehad! Jij bent 
inmiddels hard op weg om een supergoede huisarts te worden, ik gepromoveerd en over een 
paar jaar internist. Zullen we nog heel lang elkaars luisterend oor blijven, een kop thee of 
biertje drinken en Ticket to Ride spelen met de mannen?
Pimmie, één appje (of soms twee) was genoeg om je naar beneden te lokken om onder het 
genot van een bakkie koffie te discussiëren over essentiële promotiezaken, zoals wat de beste 
voetbalclub van Nederland is, waar de mooiste grasmat ligt, en of beschouwend of snijdend 
nou de mooiste tak van sport is. Veel dank daarvoor! Hou je de moed erin? Dat deed ik voor 
2017 ook al 18 jaar, dus dan hou jij het deze laatste driekwart jaar voor je boekje ook wel vol 
hè?
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Lieve Ruth, Lot en Notorious, wie had dit toch gedacht? 18 jaar geleden stonden we als 
D’tjes op het hockeyveld, nu zitten we onder het genot van een glas wijn en een lekker hapje 
eten levens- en carrière-ervaringen uit te wisselen. Dank voor alles wat ik met jullie mee heb 
mogen maken, jullie vriendschap is me ontzettend dierbaar! Ik ben trots op jullie! Ik kijk uit 
naar de vele goede avondjes die we nog voor de boeg hebben!
Lieve Juud, Sharon, Mars en Joyce, meiden, wat ben ik toch blij met jullie! Jullie hielden me 
altijd met beide benen op de grond en onze altijd hilarische dates leidden tot de broodnodige 
ontspanning bij mij! Laten we vanavond op de borrel eens een uitzondering op de regel 
maken, en voor één keer helemaal niet gezellig, luidruchtig en vervelend doen! Ik neem een 
potje kaneel mee!
Judith, lieve Juud, zo’n fijn maatje zo dichtbij, wat ben ik blij met onze vriendschap! Vriend-
schap met een kop thee die soms uitmondt in een wijntje of biertje (in de stad, nog ééntje dan), 
een luisterend oor, spelletjes met de mannen en vooral al die ongelooflijk gezellige en grap-
pige momenten (inclusief flauwe woordgrappen) die we samen mee hebben gemaakt en gaan 
maken! Daarnaast ben je één van de hele weinige personen van wie ik in al mijn eigenwijs-
heid écht nog wel eens wat aanneem! Heel veel dank voor alles, zonder jouw ontnuchterende 
Zeeuwse visie op de essentiële zaken in het leven liep ik nu denk ik nog steeds als een naïef 
kippetje zonder kop over het voetbalveld rond! Veel liefde en geluk gewenst, ook samen met 
jouw fantastische smikkelbeer-kanjers Jan en Siem. O enne... mijn naam is....^-_-^!
Lotte, lieve Lotje, ik kan eigenlijk niet goed verwoorden hoeveel onze vriendschap me waard 
is. Een half woord of zelfs maar een blik is al genoeg, hoewel ik ook altijd met heel veel plezier 
(en een kop thee en een koekje) jouw epistels lees en er één terug produceer. Dank je voor alle 
kopjes thee, koekjes, lunchjes, high teas, shopsessies, uitjes, etentjes, sushi-dates – en sinds 
vorig jaar pogingen tot het ongestoord ondernemen van eerdergenoemde activiteiten – en 
ervaringen die we over de kuikentjes uitwisselden. Jij begrijpt als geen ander hoe het is om 
alle ballen hoog te moeten houden, en je was een hele belangrijke steun voor me. Oneindig 
veel dank dat je aan mijn zijde staat op deze belangrijke dag, en natuurlijk voor je prachtige 
ontwerp van de cover van dit proefschrift. Ik wens je het allerbeste en –mooiste samen met 
jouw lieve Bas en Guusje.
Wesley, lieve Wes, collega’s en vrienden sinds we elkaar ergens in het labyrint van het Erasmus 
MC ter plaatse van de cardiologie-kelder tegen het lijf liepen, om vervolgens samen als arts-
assistent in het Amphia ziekenhuis te werken, gevolgd door een infectieziekten-gerelateerd 
promotietraject, en uiteindelijk worden we allebei internist! Om het nog maar niet te hebben 
over de goeie ski-reizen en spa’tjes geel die we samen al achter de rug/kiezen hebben! Wie 
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kan er dan beter aan mijn zijde staan op deze bijzondere dag dan jij? Veel succes met de 
laatste loodjes voor je proefschrift, en veel geluk en liefde gewenst samen met Daphne!
Djurre en Phi, ik ben blij met de familie die we vormen! Ik genoot afgelopen jaren van de 
tripjes naar Vinkeveen en de dierentuin, gourmet-sessies met de beste dresscode ever, de 
manier waarop we kerstcadeautjes verdelen en niet te vergeten een maag vol met Vietnamese 
loempia’s. Ik heb vanaf nu weer meer tijd in mijn agenda, zullen we snel lekker uit eten gaan 
met elkaar en de kindjes? Mila, mijn allerliefste grote knappe prinses, tante is hartstikke trots 
op jou! Addy, tante Puntje, we zijn completer met jou erbij. Zal ik nu toch m’n GVB maar 
gaan halen?
Lieve Alexander en Aniek, dank jullie voor jullie eeuwige interesse en support, jullie hulp 
bij het schrijven van de Nederlandse samenvatting, alle gezelligheid, de fijne etentjes en 
niet te vergeten de diensten van jullie oppasbureau! Aniek, 36 maanden promotieonderzoek 
betekent 71.459 koppen thee en 18 maanden koude voeten, toch? Ro, van jou leerde ik denk 
ik de eerste les over serendipiteit: een zeker spel genaamd Stinksok. Lien, jij begrijpt als geen 
ander wat de sleutel tot succes is: tram 4 + Capadocia. Ik ben trots op jullie!
Lieve pap en mam, vanaf het allereerste moment dat ik zei dokter te willen worden, hebben 
jullie je vertrouwen in mij uitgesproken. Ook in de afgelopen jaren, zelfs als ik zelf de moed 
dreigde te verliezen, stond voor jullie als een paal boven water dat het allemaal zou gaan 
lukken en dat ik mijn doelen zou bereiken. Pap, ik begrijp nu pas, dat mij opvoeden als 
Feyenoord-fan me in de breedste zin des woords gevormd heeft tot doorzetter pur sang! Dank 
voor jullie oneindige vertrouwen in mij en alle andere dingen die jullie voor mij en voor ons 
betekend hebben, waaronder ook alle oppas-momenten, als er weer gewerkt moest worden 
door ons. Tobias had zich geen leukere en lievere opa en oma kunnen wensen, wij ons geen 
betere (schoon)ouders, ik hou van jullie.
Lieve lieve Tobias, mannetje, wat ben ik trots op jou en wat hou ik ongelooflijk veel van je. 
Jij hebt pas echt als geen ander mijn ogen geopend voor wat ik wil, en jij vormt voor mij 
de allergrootste motivatie om dingen te doen, ze goed te doen, en ze af te maken. Zeker de 
laatste maanden waren niet altijd leuk, als ik weer eens geen tijd had om met je te spelen of 
knuffelen, maar daar gaan we verandering in brengen, hè vriendje? Heel veel kusjes!
Sander, allerliefste Sander, jij kent me zo door en door dat ik eigenlijk niet op zoek hoef 
naar woorden om je te bedanken voor alles wat je voor me betekent. Deze promotie was niet 
alleen voor mij, maar ook voor ons af en toe een behoorlijke uitdaging, die ik zonder jou nooit 
tot een goed einde had kunnen brengen. En jij werd denk ik het allermeest de dupe van het 
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gebrek aan tijd in mijn agenda. Zullen we vanaf nu maar weer gaan doen waar we echt goed 
in zijn: Genieten? Ik hou oneindig veel van je, en dank je voor alles! Kus!
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